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Abstract 
Saccharomyces cerevisiae, also known as budding yeast, has been important for human society since 
ancient time due to its use during bread making and beer brewing, but it has also made important 
contribution to scientific studies as model eukaryote. The ease of genetic modification and the 
robustness and tolerance towards harsh conditions have established yeast as one of the most 
popular chassis in industrial-scale production of various compounds. The synthesis of oleochemicals 
derived from fatty acids (FAs), such as fatty alcohols and alka(e)nes, has been extensively studied in 
S. cerevisiae, which is due to their key roles as substitutes for fossil fuels as well as their wide 
applications in other manufacturing processes. Aiming to meet the commercial requirements, efforts 
in different engineering approaches were made to optimize the TRY (titer, rate and yield) metrics in 
yeast.  
The major aim of this thesis was to enable a versatile yeast platform for the production of FA 
derivatives through diverse engineering strategies. We tested several membrane transporters for the 
potential to mediate fatty alcohol export in S. cerevisiae.  A novel function of the mammalian 
transporter FATP1 was identified as it was able to benefit fatty alcohol efflux in a high fatty alcohol 
production strain. According to the results, human FATP1 led to an improvement of extracellular 
fatty alcohols (2.6-fold increase) and cell fitness compared with the control strain. FATP1 was then 
introduced into an engineered S. cerevisiae strain carrying a heterologous 1-alkene biosynthetic 
pathway for improved 1-alkene secretion and production. Combined with an optimization of fatty 
acid metabolism and the electron transport system, a final titer of 35.3 mg/L of 1-alkenes was 
achieved with more than 80% being secreted.  
Medium-chain fatty acids (MCFAs) are non-inherent fatty acids in yeast whose microbial synthesis is 
considered to be challenging. Through expressing either an engineered native fatty acid synthase 
(FAS) or an engineered bacterial type I FAS, the synthesis of MCFAs has been successfully 
implemented in yeast. In our work, directed evolution of the native transporter Tpo1 and adaptive 
laboratory evolution were performed to increase the tolerance against MCFAs. Together with further 
augmentation of the metabolic flux towards MCFAs and optimization of the cultivation process this 
resulted in >1 g/L MCFA production. Based on the MCFA production platform, we attempted to 
synthesize medium-chain fatty alcohols (MCFOHs, C6-C12) in yeast. Different protein engineering 
strategies were designed to engineer the carboxylic acid reductase from Mycobacterium marinum 
(MmCAR), a key enzyme involved in fatty acid conversion. We successfully changed the substrate 
specificity towards MCFAs and improved the enzyme catalytic activity via directed evolution, using 
both rational and semi-rational approaches. With further deleting the TPO1 transporter gene and 
combining different MmCAR mutations, a final production of 250 mg/L MCFOHs was achieved, a 3-
fold increase compared with the control strain.   
In conclusion, we provided new insight into the establishment of yeast platforms for the production 
of FA derivatives through multidimensional engineering strategies.  
Keywords: Saccharomyces cerevisiae, fatty acid derivatives, metabolic engineering, protein 
engineering, transporter, tolerance  
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1 Introduction 
 
1.1 Saccharomyces cerevisiae as cell factory for production of diverse molecules 
 
The yeast Saccharomyces cerevisiae has been one of most frequently used microorganism 
since ancient times. In past decades, the traditional role of S. cerevisiae for bread making 
and beer brewing has been extended to the production of diverse chemicals1. S. cerevisiae, 
an intensively studied model eukaryote, has the advantage of a well-characterized genetic 
background. The ease of manipulation, the robustness and the resistance to phage 
contamination allow it to act as one of the most popular industrially applied 
microorganisms1. Additionally, the functional expression of eukaryotic cytochrome P450 
enzymes enables it to be a suitable host for the production of natural products2. Along with 
these advantages, the great interest of reconstructing biosynthesis pathways in S. cerevisiae 
has given access to the industrial production of various chemicals (Fig. 1). Owing to the 
dramatic advances in biotechnology in recent years, the biosynthesis of several natural 
products with commercial purpose as well as alternative biofuels was comprehensively 
demonstrated in yeast, which is expected to benefit the sustainable development of society. 
A number of prominent examples are presented in the following chapters.  
 
Figure 1. Reconstructing heterologous biosynthesis pathway enables the production of ethanol, oleochemicals 
and natural products. 
 
Feedstock
Biofuels Oleochemicals Natural products
ValueVolume
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1.1.1 Biosynthesis of natural products in S. cerevisiae 
 
Natural products are the metabolites produced by living organisms, of which a branch of 
secondary metabolites derived from primary metabolites is considered to be high-value 
compounds with great commercial interests as cosmetics, medicines and food additives. The 
traditional way to obtain these metabolites through directly extracting them from plants is 
often considered an inefficient and uneconomical manner that too much relies on climate 
conditions and plant life cycles3. In addition, a low yield production can be aggravated by a 
complex extraction process. Therefore, the biosynthesis of natural products in 
microorganisms as alternative method has received increasing attention and can be 
optimized to meet commercial requirements4. In many cases, the biosynthetic pathways of 
plant secondary metabolites contain multiple distinct P450 enzymes, which are anchored in 
the endoplasmic reticulum membrane by amino-terminal hydrophobic anchors5. Compared 
with the prokaryotic model E. coli, the yeast S. cerevisiae therefore represents the perfect 
host for natural product synthesis and enables further large-scale industrial production.  
Isoprenoids 
Isoprenoids, also known as terpenoids, are one of the largest classes of natural products that 
widely exist in plants, animals and microbes with currently over 40,000 molecules 
identified6. Isoprenoids can be classified as primary metabolites and secondary metabolites 
that serve a range of important physiological and societal functions7. According to the 
isoprene rule, terpenoids are formed by the repetitive joining of isoprene units linked head 
to tail8. They are typically classified, based on the number of isoprene units, as 
hemiterpenoids (C5), monoterpenoids (C10), sesquiterpenoids (C15), diterpenoids (C20), 
sesterterpenoids (C25), triterpenoids (C30), tetraterpenoids (C40) and polyterpenoids (C > 
40)8,9. Isoprenoids are derived from the universal precursors isopentenyl diphosphate (IPP) 
and its isomer dimethylallyl diphosphate (DMAPP) that contain the C5 isoprene units (Fig. 2). 
Both of the precursors can be synthesized through either the mevalonate (MVA) pathway in 
eukaryotes and cytoplasm of plants or the 2C-methyl-D-erythritol 4-phosphate (MEP) 
pathway in prokaryotes and plant plastids. The MVA pathway starts from the condensation 
of three acetyl-CoA molecules, while the MEP pathway is initiated by the condensation of 
pyruvate and glyceraldehyde-3-phosphate (G-3-P). In S. cerevisiae, the endogenous MVA 
pathway is the only route to synthesize isoprenoids (Fig. 2). The head-to-tail coupling of two 
isoprene units results in the formation of geranyl diphosphate (GPP), which is the precursor 
to monoterpenes. Additional isoprene units delivered through the MVA pathway are added 
to generate farnesyl diphosphate (FPP) and geranylgeranyl diphosphate (GGPP), the 
precursors of diverse terpenoids10.  
Various isoprenoids have been successfully synthesized in S. cerevisiae, such as limonene11, 
taxadine12, miltiradiene13, ferruginol14 and b-carotene15. The most successful story of 
terpenoid synthesis in yeast is the production of artemisinic acid, the precursor of semi-
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synthetic artemisinin that reached production at industrial scale16. In the initial strain, an 
engineered MVA pathway was used to increase FPP production in yeast; several genes 
involved in the FPP synthesis route were upregulated and one gene responsible for FPP 
degradation to sterol was downregulated17. An amorphadiene synthase (ADS) responsible 
for the first committed reaction of FPP conversion, together with a novel cytochrome P450 
monooxygenase (CYP71AV1) that performs a three-step oxidation of amorphadiene to 
artemisinic acid was successfully implemented to obtain the substrate for further artemisinin 
production17. The biosynthesis of artemisinic acid represents a significant progress in the 
development of pharmaceuticals by using synthetic biology in S. cerevisiae. 
 
 
Figure 2. Reconstructing heterologous biosynthesis pathways in yeast to produce various natural products, 
including isoprenoids, flavonoids and alkaloids. 
Flavonoids 
Flavonoids, including flavanones, isoflavones, flavones, catechins and anthocyanins, are also 
an important class of natural products containing a 15-carbon skeleton phenylpropanoid 
core, which are widely found in plants and have multiple functions. Flavonoids have been 
associated with a broad spectrum of health-promoting effects, which has stimulated large 
efforts towards the identification of their biosynthetic networks as well as the establishment 
of production platforms in microbes18–20. Flavonoids are derived from the phenylpropanoid 
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pathway in plants, which is initiated by the non-oxidative deamination of phenylalanine to 
trans-cinnamic acid via a key enzyme phenylalanine ammonia lyase (PAL)21. Trans-cinnamic 
acid is subsequently hydroxylated at the para position to generate p-coumaric acid by p-
coumaric acid cinnamate-4-hydroxylase (C4H), in conjunction with cytochrome P450 
reductase (CPR). Then, p-coumaric acid can be converted to naringenin via three enzymes, 4-
coumarate-CoA ligase (4CL), chalcone synthase (CHS) and chalcone isomerase (CHI) (Fig. 2).   
PAL and C4H as the entry point of the route were co-expressed in S. cerevisiae together with 
the reductase CPR to successfully drive the carbon flux into the phenylpropanoid pathway; 
this work was first performed by Ro and Douglas22. Naringenin serves as a key intermediate, 
from which various flavonoids can be synthesized (Fig. 2). The production of naringenin was 
significantly increased by expressing a set of genes from Arabidopsis thaliana, together with 
the deregulation of aromatic amino acid biosynthesis by alleviating feedback inhibition and 
elimination of byproduct formation resulting in a 40-fold increase of naringenin formation in 
S. cerevisiae23. The naringenin biosynthesis pathway in yeast can also be derived from 
tyrosine by introducing a tyrosine ammonia-lyase (TAL)24. With the efforts of increasing the 
malonyl-CoA supply, eliminating the feedback inhibition mediated by tyrosine and 
downregulating the competing pathways, around 90 mg/L of naringenin were obtained. 
Based on efficient synthesis of naringenin, a series of downstream flavonoid products were 
synthesized in S. cerevisiae, such as genistein25, kaempferol and quercetin26. p-Coumaric acid 
has been proven to play a crucial role in product scope determination, and also serves as the 
precursor from which the flavonoid products resokaempferol and fisetin were firstly 
synthesized in yeast26. 
Alkaloids 
As one of the large groups of natural products, alkaloids possess extremely variable chemical 
structures. Normally, an alkaloid contains at least one basic nitrogen atom in an amine-type 
structure. Alkaloids were found to exist in various organisms, such as fungi, plants and 
animals, but the functions of alkaloids in each species are diverse and yet to be fully 
understood27. Owing to the molecular complexity, the production of alkaloids through 
microbial biosynthesis is a more feasible and efficient approach compared to synthetic 
chemistry strategies. The most well-known alkaloids produced by yeast are 
benzylisoquinoline alkaloids (BIAs) and monoterpene indole alkaloids (MIAs) (Fig. 2).  
BIAs are a large and structurally diverse family that exhibits a broad range of 
pharmacological activities, which contribute to the increasing interest in their synthesis in 
microbes. BIAs share the common intermediate (S)-norcolaurine, which is generated by 
condensation of dopamine and 4-hydroxyphenylacetaldehyde (4-HPAA). Then a series of 
reactions catalyzed by norcoclaurine 6-O-methyltransferase (6-OMT), coclaurine-N-
methyltransferase (CNMT), coclaurine N-methyltransferase (NMCH) and 3ʹ-hydroxy-N-
methylcoclaurine 4ʹ-O-methyltransferase (4ʹ-OMT), is performed to produce the major 
branch point (S)-reticuline (Fig. 2). However, the two BIA backbones derived from tyrosine 
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were substantial engineering challenges, since the enzymes from plants involved in the 
conversion reactions were still not identified28. As yeast could endogenously produce 4-
HPAA, the synthesis of dopamine was the major problem for BIA production. Subsequently, 
a mammalian tyrosine hydroxylase (TyrH), bacterial DOPA decarboxylase (DODC), and four 
enzymes associated with biosynthesis of the electron carrier cofactor tetrahydrobiopterin 
(BH4) were co-expressed in S. cerevisiae to enable the de novo production of the key 
intermediate (S)-reticuline29, which represented a viable microbial production platform for 
biosynthesis of diverse BIA molecules. For example, the opioids thebaine and hydrocodone 
were recently successfully synthesized in yeast based on the optimized reticuline producing 
platform30.  
MIAs with complex structures possess diverse ranges of function as anticancer, antimalarial 
and antiaddiction drugs. The biosynthesis of strictosidine, the common precursor of MIAs, 
was recently reconstituted in yeast31. Strictosidine was formed through the condensation of 
tryptamine and monoterpene secologanin, where the tryptamine can be derived from 
tryptophan via tryptophan decarboxylase (TDC) and GPP can be converted to secologanin by 
a series of enzymes (Fig. 2). Together with some additional modifications, such as 
elimination of the byproduct pathways, the enhanced flux enabled production of 0.5 mg/L 
strictosidine. The further optimization of nepetalactol production in S. cerevisiae was 
performed, resulting in a positive effect on metabolic flux redirection towards the 
strictosidine synthesis pathway32. All these works played crucial roles in the development of 
S. cerevisiae for the sustainable production of MIAs and MIA derivatives. 
These studies demonstrated the superiority of S. cerevisiae as the chassis for the production 
of high-value natural products. The additional examples regarding the production of biofuels 
will highlight that S. cerevisiae possesses the potential as a versatile engineering and 
production platform.  
  
1.1.2 Biosynthesis of advanced biofuels in S. cerevisiae  
 
The increasing demand of fossil fuels along with environmental concerns have stimulated 
the scientific research for the development of alternative sustainable energy resources, such 
as biofuels. Bioethanol, widely applied as gasoline substitute, is mainly derived from sugar 
cane, corn or wheat. However, the use of feedstock that competes with food production 
prevents this process from further application33. Similar, the current biodiesel from oilseed 
crops faces the fact of limiting production scale due to the high demand of cultivation 
areas34. Taken these concerns, advanced biofuels produced by microbes that can be used as 
drop-in fuels were put forward to replace the first generation of biofuels. The yeast S. 
cerevisiae is the most popular workhorse for current advanced biofuel production, such as 
farnesene, butanol and hydrocarbons. 
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Butanol 
Owing to the longer chain length, butanol is in principal a more attractive biofuel than 
ethanol as it has a higher energy content, lower vapor pressure and lower hygroscopicity. 
Moreover, it has high blending percentage with gasoline, which can reach 85% compared 
with only 10% of ethanol-gasoline blending ratio33,34. The relatively high tolerance against 
butanol (up to 2%) makes S. cerevisiae a suitable chassis for microbial butanol synthesis35. S. 
cerevisiae can natively produce small amounts of butanol on rich medium through a 
pathway dependent on threonine or glycine catabolism, and deletion of Adh1 was found as a 
switch for the endogenous butanol synthesis pathway36,37. Overexpression of the pathway 
enzymes together with elimination of the competing pathways resulted in up to 242.8 mg/L 
butanol in yeast. In addition, a heterologous butanol biosynthesis pathway was 
reconstructed in yeast, which is initiated by thiolase Erg10 from acetyl-CoA, and then a set of 
heterologous enzymes, including 3-hydroxybutyryl-CoA dehydrogenase (hbd), crotonase 
(crt), trans-enoyl-CoA reductase (ter) and butyraldehyde dehydrogenase/butanol 
dehydrogenase (adhE2) enable butanol formation in yeast39. Isobutanol is one of the isomers 
of butanol whose biosynthesis pathway was fully demonstrated in yeast. Isobutanol 
synthesis was driven through valine biosynthesis pathway in S. cerevisiae, by which pyruvate 
can be converted to 2-acetolactate via acetolactate synthase (Ilv2 and Ilv6) in the 
mitochondria. Then, 2-acetolactate is converted to the key intermediate 2-ketoisovalerate 
through acetohydroxyacid reductoisomerase (Ilv5) and dihydroxyacid dehydratase (Ilv3). 
Improving the valine biosynthesis pathway to enhance the supply of 2-ketoisovalerate was a 
feasible strategy to increase the production of isobutanol in yeast, by which the isobutanol 
yield was increased from 0.28 mg/g glucose to 3.86 mg/g glucose in minimal medium39. By 
the Ehrlich pathway - similar to butanol synthesis - the ketoacid is converted into isobutanol 
in the cytosol through ketoisovalerate decarboxylases (KIVDs) and alcohol dehydrogenases 
(ADHs). The pathway was optimized by expressing the Lactococcus lactis KivD and 
endogenous dehydrogenase Adh6 that have higher catalytic activities than other 
endogenous enzymes40. Isobutanol production using S. cerevisiae has attracted much 
commercial interest that was demonstrated by a range of patents by Butalco, Butamax and 
Gevo41. With the efforts of pathway optimization, the isobutanol yield has reached 0.33 g/g 
glucose (80.3% of the maximal theoretical yield) and a final titer of 18.6 g/L of isobutanol 
was produced in complex medium42. 
Farnesene 
Farnesene is suggested to play an essential role in plants and animals and has two isomers 
a-farnesene and b-farnesene. Besides, it is also a fuel alternative that serves as a potential 
substitution for jet fuel. Farnesene, an isoprenoid hydrocarbon with a 15-carbon skeleton, 
can be synthesized based on the MVA pathway in yeast and assembled from IPP and DMAPP 
as precursors. FPP as a branch point of diverse terpenoids is natively generated in S. 
cerevisiae, while a heterologous enzyme responsible for FPP conversion needs to be 
introduced into yeast for farnesene formation43. In a previous study, both the farnesene 
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synthase and the endogenous MVA pathway were overexpressed, resulting in farnesene 
production from glucose at >50% of the theoretical mass yield44. Moreover, optimization of 
the central carbon metabolism was recently conducted by the company Amyris to enable a 
high-level farnesene producing platform in S. cerevisiae. Four non-native metabolic reactions 
performed by xylulose-5-phosphate specific phosphoketolase (xPK), phosphotransacetylase 
(PTA), acetaldehyde dehydrogenase (acylating) (ADA) and an NADH-specific HMG-CoA 
reductase (NADH-HMGr) were introduced to rewrite the central carbon metabolism, 
enabling a reduced ATP requirement for acetyl-CoA synthesis, reducing the loss of carbon 
and balancing the cofactor consumption45. The strains with optimized central metabolism 
produced 25% more farnesene than the control strain with comparable sugar consumption 
and 75% less oxygen consuming. A final titer of 130 g/L of farnesene was achieved by 
cultivating the engineered strain using industrial bioreactors after two weeks, which 
envisions the potential future large-scale industrial farnesene production in S. cerevisiae. 
Fatty acids 
Fatty acids (FAs) as versatile compounds can be utilized for industrial manufacturing of 
detergents, cosmetics and pharmaceutical ingredients. Besides, FAs also serve as the 
common precursors for a variety of biofuels, such as alka(e)nes, fatty alcohols and fatty acid 
ethyl esters. In S. cerevisiae, FAs are the basic elements of complex lipids; they can be 
incorporated into phospholipids and sphingolipids or serve as an energy reservoir in steryl 
esters (SE) and triacylglycerols (TG) stored in lipid droplets46,47. The spectrum of FAs in yeast 
is rather simple. The major components are palmitoleic acid (C16:1), oleic acid (C18:1), 
palmitic acid (C16) and stearic acid (C18); 80% of yeast fatty acids are monounsaturated 
(C18:1 and C16:1) through a reaction catalyzed by the ER-resident ∆9 desaturase Ole148,49. 
Palmitic acid is the predominant fraction among the about 20% of saturated FAs. The minor 
species including myristic acid (C14) and cerotic acid (C26) are suggested to play essential 
functions in protein modification or as components of sphingolipids and GPI-anchors, 
respectively50. Cellular fatty acids can be obtained from different sources either by de novo 
synthesis, hydrolysis of complex lipids and delipidation of proteins, and external supply46,50. 
The synthesis pathway of fatty acids has been comprehensively demonstrated, which is 
initiated by the conversion of acetyl-CoA to malonyl-CoA via acetyl-coenzyme A carboxylase 
(ACCase) encoded by ACC1 in yeast. There are two systems involved in the de novo synthesis 
of fatty acids, which are carried out by type I fatty acid synthase (type I FAS) and type II FAS 
that take place in the cytoplasm and the mitochondria, respectively. In yeast, type I FAS 
contains two multifunctional polypeptides, an α- and a β-chain encoded respectively by FAS2 
and FAS1 that form a a6b6 heterododecamer, whereas the type II FAS consists of 
monofunctional polypeptides. The mitochondrial FAS II pathway is suggested to support 
octanoic acid supply, which is the precursor for the generation of lipoic acid and plays an 
essential role in maintaining the function of several mitochondrial enzyme complexes where 
it serves as cofactors51. Since the synthesis of important storage lipids and fatty acids with 
distinct chain length all occur in the cytoplasm, the attempts for engineering fatty acid 
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metabolism are mainly focused on the type I FAS. The type I FAS catalyzes all the reactions to 
synthesize long acyl chains (mainly C14 to C18) as shown in Figure 3, and it must be 
activated by an intrinsic phosphopantetheine transferase (PPT), by which the acyl carrier 
protein (ACP) can be activated via post-translational modification to install a CoA-derived 4’-
phosphopantetheine arm (PPant) that provides thiol group to link the growing fatty acyl 
chain52,53.  
 
Figure 3. The catalytic reaction cycle of fatty acid biosynthesis and the domains in the yeast type I FAS system. 
The reactions catalyzed by the yeast FAS are initiated by transferring the acetyl primer from 
acetyl-CoA and the malonyl elongation substrate from malonyl-CoA to the ACP pantetheine 
arm with the help of the acetyl transferase (AT) and malonyl/palmitoyl transferase (MPT), 
respectively (Fig. 3). Then they are condensed by the ketoacyl synthase (KS) to form β-
ketoacyl-ACP through a malonyl decarboxylation reaction, after which the acetoacetyl-ACP 
will be further modified at its b-carbon position by ketoacyl reductase (KR), dehydratase 
(DH) and enoyl reductase (ER) yielding acyl-ACP54. The central ACP domain is located 
between the different active sites within the complex, and is responsible for shuttling the 
processed acyl-chain back to the KS domain initiating the next round of the elongation 
cycle55. In each cycle, the growing acyl-chain is elongated by C2 units provided by malonyl-
CoA until the chain length of the fatty acid reaches 16 or 18 carbon atoms. Then the end 
product will be shuttled by ACP from ER to MPT, where it is transferred to CoA and 
released56. Recently, the metabolism of S. cerevisiae was successfully changed to a pure 
lipogenesis metabolism through blocking ethanol fermentation, together with additional 
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metabolic engineering strategies for increasing acetyl-CoA and cofactor supply, enabling 
production of 33.4 g/L free fatty acids in a fed-batch cultivation57. Moreover, the fatty acid 
metabolism has been tailored to generate diverse fatty acids with distinct chain lengths. For 
example, rewiring the native fatty acid elongation system and introducing a heterologous 
Mycobacteria FAS I system, enabled a very-long- chain fatty acids (VLCFAs, C22-C26) producing 
platform in yeast58. On the other hand, the formation of short to medium-chain fatty acids 
was achieved in yeast as well by controlling the chain-length through modification of the 
yeast type I FAS59,60. 
 
1.2 Objectives and structure of the thesis 
 
The yeast S. cerevisiae as a versatile microbial cell factory, and recent studies about the 
production of natural products such as isoprenoids, flavonoids and alkaloids were 
introduced in the first part of this thesis. As mentioned, S. cerevisiae is considered as an 
attractive chassis with many advantages for future industrial biofuel production. Although 
the microbial synthesis of fatty acid-derived chemicals using S. cerevisiae has drawn much 
attention, still, many challenges and obstacles are yet to be overcome. Studies focusing on 
advanced biofuel production were also introduced in the first chapter of the thesis. The aim 
of our project was to explore the capability of yeast to enable a production platform for fatty 
acid derivatives. Details about the production of these chemicals will be discussed in the 
second chapter, including fatty alcohols, alka(e)nes and fatty acid ethyl esters. In this work, 
we applied novel multidimensional engineering approaches, such as protein engineering and 
adaptive laboratory evolution (ALE) to enable the improved production of fatty acid 
derivatives. The following parts will give a brief introduction into the work. 
The first part of the project addressed the secretion of long-chain fatty alcohols (LCFOHs, 
C12-C18) in S. cerevisiae. The accumulation of intracellular LCFOHs leads to impaired growth 
of yeast cells, which is a major obstacle of high-level production of fatty alcohols. We found 
that the heterologous fatty acid transporter FATP1 from human could also mediate fatty 
alcohol export in a high fatty alcohol producing yeast strain. With the expression of FATP1, 
improvements in fatty alcohol secretion and cell fitness were observed. Furthermore, we 
also identified the protein domain of FATP1 involved in fatty alcohol secretion through 
domain swapping with FATP4, a transporter from same family as FATP1. Engineering product 
secretion is attractive for improving the process economy and environmental friendliness61. 
In paper II, improved secretion and production of 1-alkenes in yeast were obtained through 
expression of the same transporter and other metabolic pathway engineering strategies.  
Medium-chain fatty acids (MCFAs, C6-C12) are valuable molecules that can be the substrates 
for the production of jet-fuels, gasoline, plastics and cosmetics. However, due to the toxicity 
of these non-inherent fatty acids, it is quite challenging to synthesize them by microbes62. 
We therefore attempted to improve the resistance of yeast cells against MCFAs by 
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performing directed evolution of a native membrane transporter Tpo1 and adaptive 
laboratory evolution (ALE). The work about Tpo1 transporter engineering will be introduced 
in the protein engineering section in the third chapter of this thesis. The resistance 
improvement against MCFAs using ALE will be covered in the last section of third chapter.  
Based on the high MCFA producing strain, we also attempted to synthesize medium-chain 
fatty alcohols (MCFOHs) in yeast. Although the MCFA producing strain represents a great 
platform for the synthesis of MCFOHs in S. cerevisiae, the lack of enzymes that specifically 
convert MCFAs limits the high-level production of MCFOHs. Instead of traditional metabolic 
pathway engineering, different protein engineering approaches were designed to develop an 
improved carboxylic acid reductase from Mycobacterium marinum (MmCAR), which is the 
key enzyme catalyzing the reduction of fatty acids to fatty aldehydes, which can be further 
converted to alcohols. Both the results from in vitro and in vivo tests demonstrated that we 
successfully altered the substrate specificity of MmCAR towards MCFAs and significantly 
improved the catalytic activity of the enzyme. This part of work mainly focusses on the 
engineering of the key enzymes that will be discussed in the protein engineering section. 
Accordingly, different strategies depending on random approaches and rational or semi-
rational design used to engineer MmCAR will be introduced separately.  
This thesis will give in the following a detailed introduction about how we performed the 
multidimensional engineering approaches to obtain the versatile yeast platforms for 
production of fatty acid derivatives. 
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2 Microbial synthesis of fatty acid-derived chemicals  
 
 
 
2.1 Fatty alcohols 
 
Fatty alcohols (FOHs) are considered as important chemicals widely used for the production 
of cosmetics, lubricants, plastics and potential biofuels. Microbial synthesis of fatty alcohols 
offers a solution that prevents the production from strongly relying on plant oils, which 
could enable a sustainable supply rather than competing with food oil production. Different 
routes of fatty alcohol synthesis have been established in S. cerevisiae as shown in Figure 4, 
which start from fatty acyl-CoA, fatty acyl-ACPs and fatty acids, respectively. The enzymes 
fatty acyl-CoA/ACP reductase (ACR/AAR), fatty acid reductase (FAR) and carboxylic acid 
reductase (CAR), respectively, are involved in the corresponding steps63–65. Normally, these 
enzymes catalyze a two-electron reduction to form fatty aldehydes as the intermediates, 
then followed by a second reduction via aldehyde reductases (ALRs) or alcohol 
dehydrogenases (ADHs) towards fatty alcohol generation (Fig. 4). Nevertheless, several fatty 
acyl-CoA reductases catalyzing the four-electron reduction of fatty acyl-CoA directly to the 
corresponding fatty alcohol (FaCoAR) have been identified in the jojoba plant, Arabidopsis 
thaliana and Marinobacter aquaeolei VT8, eliminating the requirement of a separate fatty 
aldehyde reductase66,67.  
The expression of NADPH-dependent FaCoAR from Mus musculus (mFAR1) in S. cerevisiae 
led to the production of 47.4 mg/L fatty alcohols68. In addition, improving the fatty acid 
synthesis pathway through replacing the native promoter of ACC1 and overexpression of 
FAS1/2 and malic enzyme, resulted in an increase in the final fatty alcohol titer to 98 mg/L. 
Being the precursors of fatty alcohols, many efforts towards optimization of fatty acid 
production have been proven to benefit fatty alcohol formation. The fatty acid degradation 
pathway was blocked through deleting fatty acyl-CoA oxidase (encoded by POX1 in yeast) 
together with deletion of fatty acyl-CoA synthetase (encoded by FAA1 and FAA4) and 
abolishing the reversal of aldehyde formation by deleting aldehyde dehydrogenase (encoded 
by HFD1), which has been reported leading to an improvement of fatty acid production in 
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yeast69. Consequently, through co-expressing the FaCoAR from Marinobacter aquaeolei VT8, 
the CAR enzyme from Mycobacterium marinum and the native alcohol dehydrogenase 
encoded by ADH5, this yielded up to 120 mg/L fatty alcohols in shake flasks. A significant 
increase in fatty alcohol production was achieved in another study, in which the authors 
deleted the competing reactions encoded by DGA1, HFD1 and ADH6, controlled cofactor 
usage by deleting GDH1 to slow down the glutamate synthesis and overexpressed the D9-
desaturase encoded by OLE1. The final strain produced 1.2 g/L fatty alcohols in shake 
flasks70.  
 
 
Figure 4. Diverse heterologous pathways for synthesis of fatty acid-derived chemicals. Acc1, acetyl-coenzyme A 
carboxylase; Fas1/2, fatty acid synthetase; Faa1/4, fatty acyl-CoA synthetase; Pox1, fatty acyl-CoA oxidase; TE, 
thioesterase; Hfd1, aldehyde dehydrogenase; ADO, aldehyde deformylating oxygenase; AD, aldehyde 
decarbonylase; ADH, alcohol dehydrogenase; ALR, aldehyde reductase; ACR/AAR, fatty acyl-CoA/ACP 
reductase; FAR, fatty acid reductase; CAR, carboxylic acid reductase; FAP, fatty acid photodecarboxylase; Ols, 
olefin synthetase; WS/DGAT, wax ester synthase/acyl-CoA: diacylglycerol acyltransferase.The enzymes in black 
are involved in the synthesis process, and the knockout of the enzymes in red has been shown to have a 
positive effect on the production of FA derivatives.  
Many of the metabolic engineering approaches have been applied to enable an efficient 
yeast cell factory with high levels of fatty alcohols being produced. However, the impaired 
growth attributed to the accumulation of fatty alcohols and the high extraction costs for 
intracellular products are major obstacles for large-scale industrial production69. The aim of 
the first part of this project (Paper I) was therefore to identify fatty alcohol exporters that 
could benefit the cell growth and fatty alcohol secretion.  
The metabolism for fatty alcohol production had been optimized in a previous study from 
our group69, and around 1.5 g/L of fatty alcohols were obtained in a fed-batch culture from 
the final strain, FOH33, in which the enzymes involved in fatty alcohol synthesis including 
heterologous reductases MmCAR and FaCoAR and endogenous alcohol dehydrogenase Adh5 
were overexpressed. In addition, the genes POX1, FAA1, FAA4, HFD1, and ADH6 responsible 
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for competing pathways were deleted in the same strain. However, the large amount of 
intracellular fatty alcohols accumulated in this strain led to impaired cell growth. In order to 
relieve the cellular toxicity, we attempted to identify transporters that facilitate fatty alcohol 
export in this strain. As no specific fatty alcohol transporters had been reported and 
substrate specificity of known transporters was the theoretical basis for choosing 
transporter candidates, we assumed that transporters for fatty acids could also recognize 
fatty alcohol as the substrate due to the similar structures. Thus, several fatty acid and wax 
transporters from different species were selected and expressed in S. cerevisiae. The 
candidate transporters are listed in Table 1.   
 
      Table 1. List of fatty alcohol transporter candidates. 
Name Species Description Reference 
ABCB1 H. sapiens 
 
 
Regulation of the efflux of phospholipid, long-chain fatty 
acids, cholesterol, etc. 
71,72 
ABCG11 A. thaliana 
 
Epidermal plasma membrane cuticular lipid exporter. 
Functions as homodimer or heterodimer with ABCG9, 
ABCG12, and ABCG14. 
73 
ABCG12 A. thaliana 
 
Plant cuticular wax exporter. Functions as a heterodimer with 
ABCG11. 
74,75 
ABCG9 A. thaliana 
 
Half transporter, which works with ABCG11 as heterodimer or 
homodimer. It is involved in lipid/sterol homeostasis 
regulation. 
75 
ABCG14 A. thaliana 
 
Half transporter, which works with ABCG11 as heterodimer. It 
is involved in lipid/sterol homeostasis regulation. 
75–77 
FATP1 H. sapiens 
 
Long-chain fatty acid uptake transporter of the FATP family, 
which has acyl-CoA synthetase activity. 
78,79 
FATP4 H. sapiens 
 
Transporter of the FATP family that facilitates long-chain and 
very long-chain fatty acid uptake. 
80,81 
CD36 H. sapiens 
 
A transporter protein that enhances cellular fatty acid uptake. 82,83 
 
All of the transporter genes were codon-optimized and evaluated in strain FOH33 through 
assessing the extracellular fatty alcohols, among which FATP1 was the only one found to 
dramatically increase the final titer of extracellular fatty alcohols, resulting in 70 mg/L 
compared to 16 mg/L produced by the control strain (Fig. 5). In addition to elevated 
secretion of fatty alcohols, FATP1 expression in yeast also resulted in a higher biomass yield, 
i.e. an 83% increase of final cell mass (Fig. 5), suggesting that the expression of FATP1 was 
beneficial for relieving the cellular toxicity by exporting the intracellular fatty alcohols out of 
the cells. For the other transporters, their expression negatively affected the final biomass 
yield (OD600) and the final titer of extracellular fatty alcohols, which were even lower than 
found for the control strain.  
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Figure 5. Extracellular fatty alcohol titers and final OD600 of S. cerevisiae strain FOH33 expressing different 
heterologous transporters. Adapted from Hu et al. 84 
FATP1 belongs to the FATP family in human containing six FATP isoforms (FATP1-6). All of 
the members have been identified as dual-functional proteins that mediate fatty acid uptake 
and have fatty acyl-CoA synthetase activity in human cells78,85–88. Although all the members 
share a well-conserved 311-amino acid sequence, each of them showed different capacities 
in fatty acid uptake and activation79. Based on previous studies, FATP1 was known as fatty 
acid transporter that facilitates the uptake of long-chain fatty acids (LCFAs)89, and the similar 
property of LCFAs uptake was observed in a yeast strain expressing FATP1 using LCFAs as the 
sole carbon source79. As the modifications in the host strain FOH33 including deletion of 
FAA1/4 and overexpression of FaCoAR might cause the scarcity of acyl-CoA that is essential 
for cell growth, we therefore speculated that the increase in biomass formation might 
partially be due to the long-chain fatty acyl-CoA synthetase activity of FATP1, since the 
activation of long-chain fatty acids to form acyl-CoA could potentially complement the 
deficiency of Faa1/4 in this strain.  
In order to investigate if other FATPs have similar effects on fatty alcohol secretion, we thus 
tested all six isoforms (FATP1-6) in the FOH33 strain. However, even less extracellular fatty 
alcohols were detected by GC-MS compared with control strain, and none of the these was 
able to facilitate fatty alcohol export except FATP1 (Fig. 6a). In addition, according to the 
final OD600, the expression of FATP2, FATP3, FATP5 and FATP6 had no positive effect on the 
cell growth except FATP4, as the strain containing FATP4 resulted in a relatively high final 
OD600 that was around 9. (Fig. 6b). However, although the expression of FATP4 did benefit 
the cell growth of FOH33, an increase in extracellular fatty alcohols was still not observed, 
suggesting that the fatty alcohol export activity was specific to FATP1. The result was also 
consistent with our hypothesis that the fatty acyl-CoA synthetase activity could potentially 
also contribute to the improvement in cell growth. 
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Figure 6. The effect of expression of FATP family transporters in a high fatty alcohol production yeast strain, 
FOH33. (a) GC spectra of strains based on FOH33 containing FATP transporter isoforms. FOH33 carrying the 
empty vector pIYH01 was used as control. (b) The final biomass (represented as OD600) of FOH33-derived 
strains expressing FATP proteins or carrying an empty vector. Increased production of extracellular fatty 
alcohols (+) or no effect (-) compared to control strain is indicated according to (a). Adapted from Hu et al.84 
 
We analyzed the profile of fatty alcohols produced by the FATP1 expressing strain. Around 
70 mg/L extracellular fatty alcohols were obtained from shake-flask cultivations, which was 
4.5-fold higher than the final titer of the control strain (ca. 15 mg/L) (Fig. 7a). In addition, an 
increase in the titer of intracellular fatty alcohols was also obtained in the FATP1 expressing 
strain, resulting the production of 170 mg/L intracellular fatty alcohols compared to 120 
mg/L in the control strain (Fig. 7b). Moreover, extracellular fatty acids were also detected, 
and the final titer was around 190 mg/L, showing that the level of extracellular fatty acids in 
the FATP1 expression strain was also enhanced compared with the control strain (60 mg/L) 
(Fig. 7c). The growth curves of the control strain and FATP1 expressing strain are shown in 
Figure 7d. FATP1 enabled both a faster growth rate and higher final cell mass than the 
control strain (Fig. 7d). The specific yield co-efficient of fatty alcohols was investigated to 
determine whether the increased extracellular fatty alcohols resulted from the higher 
biomass concentration. Although the specific yield of total fatty alcohols in the FATP1 
expressing strain was even slightly lower than for the control strain, according to the results, 
the FATP1 expression strain produced 6.4 mg/L/OD of extracellular fatty alcohols, which 
accounted for 29% of the total fatty alcohol products, while the control strain only produced 
2.4 mg/L/OD of extracellular fatty alcohols (Fig. 7e). In conclusion, with the FATP1 
transporter expression, the final titer of extracellular and total fatty alcohols increased 
around 4.5- and 2-fold, respectively, and the cell growth also benefitted from FATP1 
expression as a 2-fold increase in the final biomass was obtained.   
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Figure 7. The effect of FATP1 expression on extracellular fatty alcohols, intracellular fatty alcohols and cell 
growth.  (a) Final titers of extracellular fatty alcohols produced by FOH33 and FATP1 expressing strain. (b) 
Intracellular fatty alcohol titers produced by control strain FOH33 and FATP1 expressing strain. (c) Final titers of 
extracellular fatty acid produced by FOH33 and FATP1 expressing strain. (d) Growth curves of FOH33 and FATP1 
expressing strain. (e) The yield of fatty alcohols (including both extracellular and intracellular fatty alcohols) 
from FOH33 and FATP1 expressing strain, and the distribution of extracellular and intracellular fatty alcohols 
for each strain. Adapted from Hu et al.84 
 
FATP4 has been proven to benefit the growth of FOH33 with no fatty alcohols being 
secreted, which potentially resulted from its function as acyl-CoA synthetase. Therefore, 
there might be no direct connection between fatty alcohol export and fatty acid activation 
activities. As FATP1 was found to be the only functional transporter for fatty alcohols, we 
wanted to identify which protein domain of FATP1 can confer the ability to transport fatty 
alcohols to FATP4. Thus, a domain exchange strategy was applied between FATP1 and 
FATP4. All members of FATP family contain an intrinsic well-conserved FATP/VLCS motif and 
an ATP/AMP motif, which have been reported to contribute to the fatty acyl-CoA synthetase 
activity a and are commonly found in all adenylate-forming enzymes90,91. Each gene was 
divided into three domains based on the corresponding amino acid sequence. The first part 
(F1 and F4) at the N-terminus was the region upstream of the respective ATP/AMP motifs of 
FATP1/4, the middle part (F2 and F5) contained the ATP/AMP motifs, and the last part (F3 
and F6) covered 143 amino acids containing the FATP/VLCS motif (Fig. 8a). The three 
domains from FATP1 and FATP4, respectively, were fused with each other to generate six 
new FATP chimeras, FATP423, FATP153, FATP126, FATP156, FATP426 and FATP453 (Fig. 8a).  
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Figure 8. Effect of six FATP chimeras resulting from domain swapping. (a) Division of FATP1 and FATP4 into 
three domains to construct six new FATP chimeras. (b) Effect of expressing six new chimeras on yield of 
extracellular fatty alcohols and the final biomass of each strain. Adapted from Hu et al.84 
After transforming FOH33 with the chimeric constructs, the final biomass of all 
transformants was much lower compared to the FATP1 and FATP4 expressing strains, 
suggesting that the fatty acyl-CoA activity in the new isoforms may have been affected after 
the domain exchange (Fig. 8b). However, these chimeras possess distinct efficiencies in fatty 
alcohol transport, as an increased yield of extracellular fatty alcohols was only observed in 
the strains with FATP423, FATP126 and FATP426 (Fig. 8b). According to the results, 3.9, 4.9 
and 4.1 mg/g DCW was the yield of extracellular fatty alcohols obtained from strains 
containing FATP423, FATP126 and FATP426, respectively a more than 2-fold increase 
compared to the strain with FATP4. Interestingly, all the three efficient FATP chimeras 
shared a common F2 domain that contains the ATP/AMP motif from FATP1, which indicated 
that the F2 domain contributed the most to the fatty alcohol export activity. This suggested 
a conclusion distinct to a former report, which suggested that the FATP/VLACS motif of yeast 
FATP orthologue Fat1 showed specific functions for fatty acid uptake92. However, after the 
further introduction of two mutations into Asp508 to abolish ATP binding in FATP1 (see Figure 
S4 in Paper I), the mutants lost their function as fatty alcohol transporter, which reveals a 
consistent conclusion that the ATP/AMP motif played a critical role in fatty alcohol export in 
FATP1.  
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In this study, we identified a novel function of transporter FATP1, and significantly improved 
the fitness of a biofuel production strain as well as the secretion and production of fatty 
alcohols. This work highlights the possibility that transporter engineering could be a 
promising strategy to enable the successful commercialization of biofuel production.  
 
2.2 Alka(e)nes  
 
Alkanes and alkenes synthesized by microbes are attractive drop-in biofuels that could be 
utilized as gasoline, diesel and jet fuel. They are produced naturally by many organisms 
where they have distinct functions, for example, as plant cuticular waxes and insect 
pheromones93,94. The first success of heterologous de novo synthesis of alkanes was 
obtained in E. coli95. The authors identified an alkane biosynthesis pathway from 
cyanobacteria and introducing the pathway into E. coli by expressing a cyanobacterial AAR 
and a fatty aldehyde deformylating oxygenase (ADO), the fatty acid metabolism was 
successfully directed towards alka(e)ne production (Fig. 4). Later, the de novo synthesis 
pathway was elucidated in yeast as well.  
Fatty acids, fatty acyl-ACP/CoA and fatty aldehydes are the major precursors that can be 
used to synthesize alka(e)nes in S. cerevisiae via corresponding enzymes. OleTJE was 
reported as a cytochrome P450 enzyme from the CYP152 family that is responsible for the 
conversion of C12-C20 fatty acids to corresponding terminal olefins (1-alkenes) using H2O2 as 
the sole electron and oxygen donor96,97. UndA and UndB were identified as fatty acid 
decarboxylases that also use fatty acids as the precursor, but with a substrate specificity 
towards medium-chain fatty acids (C10-C16) (Fig. 4), yielding medium-chain 1-alkenes. 
Furthermore, an algal fatty acid photodecarboxylase (FAP) driven by light was recently found 
that can facilitate the conversion of fatty acids to their corresponding alka(e)nes, and this 
enzyme was applied successfully in E. coli to generate hydrocarbons in the presence of 
visible light98. The synthesis of alka(e)nes can also be initiated from fatty aldehydes by 
aldehyde deformylating oxygenase (ADO) or aldehyde decarbonylase (AD). ADO is 
considered as a non-haem di-iron oxygenase requiring molecular oxygen and an external 
reducing system to provide four electrons, yielding hydrogen peroxide (H2O2) and formate as 
by-products99. AD catalyzes the decarbonylation of fatty aldehydes to alka(e)nes. Drosophila 
CYP4G1 and Arabidopsis CER1 with the associated protein CER3, the most well-known ADs, 
are naturally involved in long-chain alkane biosynthesis and have been successfully 
expressed in yeast to generate alka(e)nes100,101. Finally, a multi-domain polyketide synthase 
(PKS) from cyanobacteria, referred to as Ols (Fig. 4), can catalyze the reaction from fatty 
acyl-CoA/ACP to alka(e)nes through an elongation/sulfonation/decarboxylation 
mechanism102. 
Many studies focusing on the biosynthesis of alka(e)nes in S. cerevisiae achieved significant 
progress during recent years. However, one reason for the suboptimal titers of alka(e)ne 
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production in yeast is the low efficiency of the enzymes involved and the strong competition 
of fatty alcohol accumulation103. Compartmentalization by targeting the enzymes involved in 
alka(e)ne production to the peroxisomes in this case, has been proven to be a feasible 
strategy with the advantage of isolating the synthesis pathway from the competing routes in 
the cytosol. In a previous study, Synechococcus elongatus ADO (SeADO) together with 
Mycobaterium marium CAR (MmCAR) was targeted to the peroxisomes in yeast resulting in 
around 0.12 mg/L alkanes, 90% more alkanes than produced by the cytosolic pathway104.  A 
similar approach was applied successfully to improve medium chain alka(e)ne (C7-C13) 
production in yeast105. Besides the inefficiency of the synthesis pathway, also the toxicity 
caused by accumulation of alka(e)nes limits production in the cells, which has stimulated 
some studies focusing on the tolerance increase against alka(e)nes. Both endogenous and 
heterologous transporters were identified in S. cerevisiae to benefit the cellular tolerance 
against alka(e)nes, for example, the native efflux pumps Snq2 and Pdr5 and the exporters 
Abc2 and Abc3 from Yarrowia lipolytica106,107. As part of the project, we aimed to engineer 
an ideal yeast cell factory for the production and secretion of 1-alkenes by pathway 
engineering, overall dynamic metabolic balancing and transporter expression (Paper II). 
 
Figure 9. The titer of 1-alkenes produced by S. cerevisiae strains expressing different heterologous enzymes. 
The host strain used for evaluation was the fatty acid over-producing strain YJZ06 carrying deletions of POX1, 
FAA1 and FAA4. Adapted from Zhou et al.108 
Concerning alka(e)ne production, there is a performance variation observed in yeast and E. 
coli with the potential reasons for these differences being protein expression level and/or 
enzymatic activity in the cellular environment. We therefore initiated this work with a 
screening for more efficient pathways for terminal alkene production in the fatty acid over-
producing yeast strain YJZ0669, which carries deletions of FAA1/4 and POX1. Besides H2O2-
dependent P450 enzyme OleT, we also tested the recently identified nonhaem iron oxidase 
UndA and desaturase-like enzyme UndB. All these fatty acid decarboxylase genes were 
expressed under control of an enhanced strong promoter eTDH3p from the pYX212 plasmid 
backbone. Expression of OleT from Jeotgalicoccus enabled production of 0.92 mg/L 1-
alkenes, while PpUndA from Pseudomonas putida F1 led to a lower 1-alkene titer of 0.57 
mg/L (Fig. 9). The distinct efficiency of PpUndA for medium-chain 1-alkene production 
observed previously was reflected in the fact that this enzyme seemed to have poor activity 
towards long-chain fatty acids in our study109. Interestingly, UndB, the desaturase-like 
enzyme, catalysed the biosynthesis of 1-alkenes in S. cerevisiae with the highest efficiency. 
(Fig. 9). Two UndB enzymes, PmUndB from Pseudomonas mendocina and pfUndB from 
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Pseudomonas fluorescens Pf-5, were evaluated in the yeast strain, of which the latter 
showed higher activity in 1-alkene production, resulting in 5.76 mg/L of 1-alkenes.  
The correlation between free fatty acid accumulation and 1-alkene production is of great 
interests to be investigated (Fig. 10). From the results, marginal effects on 1-alkene 
production were observed in strains deficient of Pox1 and/or Faa4, while a 36% increase in 
the final titer was obtained after the deletion of FAA1. The triple deletion led to 6.20 mg/L of 
1-alkenes, which was a 2.8-fold increase compared to the strain with wild-type background. 
Furthermore, we found that the production of 1-alkenes was well correlated with the free 
fatty acid levels, which was consistent with previous studies 110(Fig. 10). These results 
suggested fatty acid decarboxylase needs sufficient levels of precursor free fatty acids. 
 
 
Figure 10. The effect of manipulating the levels of free fatty acids on biosynthesis of 1-alkene. Adapted from 
Zhou et al.108 
Electron transfer is involved in terminal alkene biosynthesis, as it is an oxidation process. 
From several previous studies, it was shown that an efficient reduction system can positively 
affect fatty acid decarboxylases both in vitro and in vivo111. We thus tried to introduce and 
compare three electron transfer systems, which were ferredoxin-ferredoxin reductase 
(Fd/Fpr) and flavodoxin-ferredoxin reductase (Fld/Fpr) from E. coli using NADPH as cofactor, 
putidaredoxin-putidaredoxin reductase from P. putida (Pdx/Pdr, encoded by camB and 
camA, respectively) using NADH as cofactor (Fig. 11a). According to the results, the 
ferredoxin and flavodoxin based electron transfer system enabled a 42% and 58% 
improvement in 1-alkene production, respectively, while a 108% increase in 1-alkene 
production was obtained with the putidaredoxin reductase system (Fig. 11b). However, 
efforts towards electron channelling optimization through fusing the Pdx/Pdr system to 
PfUndB with different linkers did not yield a higher 1-alkene production (see Figure S1 in 
Paper II). It is still worth to mention that the utilization of NADH as electron donor provides a 
great advantage for 1-alkene synthesis in yeast, which has much higher (>7-fold) levels of 
NADH compared NADPH112. 
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Figure 11. The effects of different electron transfer systems on total 1-alkene production. (a) Overview of the 
1-alkene synthesis pathway including Fd/Fnr, Fld/Fnr and Pdx/Pdr electron transfer systems. (b) The titer of 1-
alkenes in different engineered strains. Adapted from Zhou et al.108 
We found that there was high ratio of terminal alkene secreted, as UndB was reported as a 
membrane-bound desaturase-like enzyme 113(see Figure S2 in Paper II). Fluorescence 
microscopy analysis of a UndB-GFP carrying strain AE17 showed that the GFP signal mainly 
localized to the membrane (Fig. 12a and 12b). Here, the strong promoter eTDH3p was used 
to enable high-level expression of PfUndB, but this resulted in impaired growth in strain 
AE24 (Fig. 12c), which might be attributed to the eTDH3p-based transcription being strongly 
upregulated in the glucose phase and the high-level expression of a membrane protein 
might cause stress resulting in poor cell growth. We therefore fine-tuned the expression of 
undB by utilizing a dynamic control system, in which the cell growth and 1-alkene production 
could be separated by controlling the enzyme expression via carbon source dependent 
promoter GAL7. Thus, the expression of PfUndB was repressed at high glucose levels and 
activated at glucose depletion under the control of GAL7p combined with the deletion of the 
transcription factor Gal80 in the strain AE38. The final titer of 1-alkenes reached 25 mg/L, 
leading to a 100% higher final titer of 1-alkenes compared to strain AE24 constitutively 
expressing PfUndB under control of eTDH3p (Fig. 12c). Both strains had high proportion of 
extracellular 1-alkenes (>60%) and the dynamic control of PfUndB improved the 1-alkene 
production, both intracellular and extracellular (see Figure S2 in Paper II). In addition, a 
better cell growth was observed in strain AE38, which had a higher final biomass and higher 
glucose consumption rate compared to AE34 (Fig. 12c and see Figure S3 in Paper II). Besides, 
compared with AE34, a higher 1-alkene production (Fig. 12c) and lower accumulation of FFA 
were obtained from strain AE38 (see Figure S4 in Paper II). As consequences of performing 
the dynamic control, the toxicity of 1-alkenes was relieved by expressing the membrane 
protein PfundB and the dynamic control of the expression of the membrane protein enabled 
an increase in the production, which indicated a feasible approach to benefit a cell factory 
producing toxic chemicals.     
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Figure 12. The effects of dynamic control of the expression of membrane enzyme UndB and transporter 
expression. (a) Overview of 1-alkene production and secretion (b) Fluorescence microscopy of strain AE17 
containing undB fused with GFP. (c) The comparison of 1-alkene production and OD600 of strain AE38 and 
AE34. The UndB gene was controlled by GAL7p in AE38 and controlled by eTDH3p in AE34. (d) The effect on 
total 1-alkene production with LCFA transporter FATP1 expression. Strain AE39 contains FATP1 and strain AE38 
does not. (e) The profiles of total 1-alkenes in strain AE38 and AE39 at 48 h and 70 h. Adapted from Zhou et 
al.108 
The improvement of secretion has been proven to be a cost-efficient manner that could 
reduce the cost for downstream extraction and purification. Many transporters, such as 
resistance-nodulation-cell division (RND) or ATP-binding cassette (ABC) transporters114,115, 
have been successfully utilized to enhance the production and secretion in previous studies. 
As introduced previously, we identified the novel function of FATP1 as LCFOH exporter in S. 
cerevisiae in Paper I. Here, we wanted to explore the potential capability of FATP1 to 
facilitate 1-alkene secretion based on the similar hydrophobic property of both LCFAs and 1-
alkenes (Fig. 12a). As FATP1 is a membrane protein, the inducible promoter HXT6p was used 
to separate the cell growth and production process. Coupled to HXT6p FATP1 was expected 
to be highly expressed after glucose depletion and thus coupled to 1-alkene production. A 
marginal effect on cell growth and fatty acid production was obtained after integration of 
the FATP1 expression cassette in strain AE39 (see Figure S5 in Paper II), but the extracellular 
and total 1-alkene production both showed a significant improvement after 70 h cultivation, 
which was 40% and 37% higher than for the control strain AE38, respectively (Fig. 12d). The 
FATP1 expressing strain had more than 81% 1-alkenes secreted out of the cells. Although 
there was little difference in the 1-alkene profiles between AE38 and AE39, slightly more C17 
1-alkenes were accumulated at 70 h compared with at 48 h (Fig. 12e). 
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In this part of work, we engineered a high 1-alkene production and secretion yeast platform 
by cofactor engineering, transporter engineering and dynamic enzyme control. This study 
also indicated that the product secretion would provide great benefits for industrial 
production as it will decrease the separation costs. 
 
2.3 Fatty acid ethyl esters 
 
Fatty acid ethyl esters (FAEEs) are secondary metabolites naturally produced by S. cerevisiae 
that usually play key roles as flavor compounds. Biodiesel consists of monoalkyl esters of 
long-chain fatty acids with short-chain alcohols, primarily methanol and ethanol, i.e. fatty 
acid methyl esters (FAMEs) and FAEEs. Due to the high toxicity of methanol to the cells116, 
the precursor of FAMEs, an increasing interest has been put on the microbial synthesis of 
FAEEs as a substitute of diesel and bunker oil. Ethanol and acyl-CoAs are the essential 
precursors that are involved in the biosynthesis of FAEEs, a process with esterification as the 
mechanism. Esterification is defined as the formation of an ester from alcohols and 
carboxylic acids, here catalyzed by the wax ester synthases/acyl-CoA: diacylglycerol 
acyltransferases (WS/DGAT) (Fig. 4), which naturally accept acyl groups with a chain length 
of C16 or C18 and linear alcohols with a chain ranging from C12 to C20117. WSs can have 
different preferences for substrates with distinct chain length, which enables diverse 
applications for ester products, such as jojoba-like wax esters and fatty acid ethyl esters118.  
A highly unspecific WS/DGAT from Acinetobacter calcoaceticus ADP1 was firstly tested in S. 
cerevisiae, resulting a poor performance in FAEE production119. Then, five heterologous WSs 
from bacteria and mammals were evaluated in yeast to investigate their substrate 
preferences. The results showed that the WS from Marinobacter hydrocarbonoclasticus had 
the best performance towards ethanol as the substrate in vitro and led to the highest FAEE 
titer of 6.3 mg/L in S. cerevisiae118. Then, chromosomal integration of multiple gene copies 
yielded a six-fold improvement, up to 34 mg/L, of FAEEs compared to the plasmid-based 
producer. A further 40% increase in FAEE production was obtained when the precursor 
supply was improved through overexpression of acyl-CoA binding protein (encoded by ACB1) 
and when the NADPH level was elevated by expression of a bacterial NADP+-dependent 
glyceraldehyde-3-phosphate dehydrogenase (GAPN)120. In order to achieve efficient 
synthesis of FAEEs, the concentration of free fatty acids as the precursor would affect the 
final titer. In S. cerevisiae, FAs are used to synthesize phospholipids and storage neutral 
lipids. The major FA reserves, triacylglycerols (TAGs) and steryl esters (SEs), can constitute 
about 97% of the storage lipid content of the cell and are not essential to the cell121. Blocking 
the pathways competing for FAs by deleting the genes involved in TAG and SE synthesis 
(DGA1, LRO1, ARE1 and ARE2) was beneficial for FA accumulation and in turn increased the 
FAEE production 2.5-fold122. Meanwhile, also acetyl-CoA as the common precursor for fatty 
acid derivatives was considered to play a key role in FAEE production. The flux towards 
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acetyl-CoA was improved by overexpressing alcohol dehydrogenase (encoded by ADH2), 
acetaldehyde dehydrogenase (encoded by ALD6) and ACS encoded by heterologous gene 
aceSEL641P, together with the integrated ws2, which led to a three-fold increase of FAEE 
production123. Then, acetyl-CoA was further increased by the phosphoketolase (PHK) 
pathway through the expression of xpkA and either ack from Aspergillus nidulans or pta 
from Bacillus subtilis (a more detailed description of the enzymes will be provided in the 
following chapter). The introduction of the heterologous PHK pathways helped to produce 
around 5 mg/g cell dry weight FAEEs, an up to a 1.7-fold improvement. Instead of traditional 
carbon sources, such as glucose and sucrose, the microbial fermentation using glycerol has 
been extensively studied due to several advantages including a highly reduced substrate and 
the cost advantage of anerobic processes with less energy requirements. By increasing the 
ethanol formation from glycerol, together with blocking the glycerol export route and adding 
exogenous fatty acids, the titer of FAEEs reached 0.52 g/L which is the highest reported FAEE 
production to date in yeast124.  
Although it seems unlikely that the concentration of FAEEs reported so far is toxic to the 
cells, the engineering of transporters specific towards FAEEs that potentially benefit the 
secretion would still be a feasible strategy to further improve the production of FAEEs in the 
long term.  
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3 Strategies for improving the production of fatty acid derivatives 
 
 
 
3.1 Modifications of central carbon metabolism  
 
Glucose is the most widely studied carbon source of wild-type S. cerevisiae that can be 
transported into yeast cells by the membrane hexose transporters via facilitated diffusion. 
The members of the hexose transporter (HXT) family differ with each other in their 
transcriptional and posttranscriptional regulation, substrate specificity and affinity for 
glucose125. After the uptake, glucose is then cleaved into three-carbon units via the glycolysis 
pathway.  
Glycolysis is the critical metabolic pathway for the growth of all organisms and is responsible 
for the assimilation of carbon for either respiration or fermentation126,127. In the beginning of 
glycolysis, glucose is phosphorylated by a hexokinase (encoded by HXK1, HXK2 and GLK1) 
yielding glucose-6-phosphate (G6P) through transferring the phosphoryl group from ATP to 
the hydroxyl group of glucose. Followed by an isomerization and another phosphorylation 
that are catalyzed by phosphoglucose isomerase (encoded by PGI1) and 
phosphofructokinase (encoded by PFK1 and PFK2), respectively, glucose is converted into 
fructose 1,6-bisphosphate (F1,6P). Next, the six-carbon F1,6P is cleaved into two three-
carbon metabolites glyceraldehyde 3-phosphate (G3P) and dihydroxyacetone phosphate 
(DHAP) under a reversible condensation catalyzed by fructose-biphosphate aldolase 
(encoded by FBA1). There has been no energy generated so far, to the contrary, two 
molecules of ATP have already been invested. In the remaining steps of glycolysis, the flux 
will continue from G3P to form pyruvate under a series of reactions with two molecules of 
ATP being generated. The first ATP in glycolysis is produced during the conversion from 1,3-
bisphosphoglycerate (BPG) to 3-phosphoglycerate (3PG) via phosphoglycerate kinase 
(encoded by PGK1). And another ATP is generated along with the pyruvate formation from 
phosphenolpyruvate (PEP) catalyzed by pyruvate kinase (encoded by PYK1 and PYK2). In 
yeast, pyruvate is located at a major junction of assimilatory and dissimilatory reactions, 
which is also considered as the branch-point between respiratory dissimilation of sugars and 
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alcoholic fermentation128. As an essential precursor for acetyl-CoA synthesis, pyruvate has 
two major metabolic fates. First, pyruvate can be transported into mitochondria facilitated 
by the mitochondrial pyruvate carrier (MPC) protein (encoded by MPC1, MPC2 and MPC3), 
and then oxidized by the pyruvate dehydrogenase complex (PDH) to generate acetyl-CoA to 
enter the tricarboxylic acid (TCA) cycle128,129. Second, pyruvate can be converted to acetyl-
CoA in the cytosol via three reactions catalyzed by pyruvate decarboxylase (encoded by 
PDC1, PDC5 and PDC6), acetaldehyde dehydrogenase (encoded by ALD2/3/4/5/6) and 
acetyl-CoA synthetase (encoded by ACS1 and ACS2). In addition, pyruvate can be the 
substrate for alcoholic fermentation reducing it to ethanol primarily catalyzed by alcohol 
dehydrogenase 1 (encoded by ADH1) with acetaldehyde as the intermediate.  
Eliminating alcoholic fermentation 
Whenever yeast exhibits a fermentative sugar metabolism, ethanol and carbon dioxide are 
the predominant fermentation products130. The wide application of microbial synthesis has 
stimulated the further improvement of the yield of the desired products. In the case of yeast 
as the host organism, attempts of redirecting the carbon flux away from alcoholic 
fermentation towards the desired products have been made in recent years. Acetaldehyde, 
as the intermediate generated from pyruvate, is also the precursor for ethanol production. 
Thus, the deletion of the ADH genes, together with overexpression of the ALD and the 
heterologous ACS were conducted to prevent the conversion from acetaldehyde to ethanol 
and augment the flux towards acetyl-CoA131. However, the formation of ethanol is not 
entirely eliminated in yeast by simply deleting ADH genes, as there is a large number of 
promiscuous ADHs that could catalyze the reaction to generate ethanol and many of those 
ADHs are also involved in the production of other essential metabolites within the cells132. 
 
Figure 13. Engineering strategies for eliminating alcoholic fermentation in yeast cells. Pyk, pyruvate kinase; Pdc, 
pyruvate decarboxylase; Adh, alcohol dehydrogenase; Ald, acetaldehyde dehydrogenase; Acs, acetyl-CoA 
synthetase; Ach, acetyl-CoA hydrolase. 
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Instead, ethanol formation was inhibited by the knockout of all three Pdc enzymes (PDC1, 
PDC5 and PDC6)133 (Fig. 13). However, the glucose sensitivity, as the general characteristic of 
the Pdc-negative strain, makes it unable to grow in excess glucose, which is due to the 
repression of respiratory metabolism and the deficiency of C2 supply in the cytosol. The 
extended cultivation under conditions in which the Pdc-negative strain would not grow 
offered a solution through generating spontaneous mutants. The problem was solved by 
evolving the Pdc-deficient strain, which succeeded in obtaining a C2-independent Pdc-
negative strain that could also grow in excess glucose133. From the evolved strain, an internal 
deletion in a transcriptional regulator, Mth1, which is involved in glucose sensing in yeast, 
was found to be associated with the restored growth of the Pdc-negative strain134. With this 
mutated Mth1, the glucose flux was reduced thus resulting in decreased repression of 
respiration in the evolved strain (Fig. 13). As mentioned above, the block of ethanol 
synthesis by deletion of all three PDC genes will also inhibit the formation of cytosolic acetyl 
units that serve as precursors for various downstream products, such as fatty acids. Later, 
the mitochondrial Ach1 was found to facilitate the formation of acetate from acetyl-CoA 
(Fig. 13), which can then enter the cytosol to provide C2 units for cytoplasmic acetyl-CoA 
synthesis and thus compensates for the lack of cytosolic acetyl-CoA supply via the PDH 
bypass135. However, this route cannot function under glucose-repressed conditions and is 
restricted by the limited mitochondrial acetyl-CoA supply due to the stringent regulation of 
the PDH complex. Alternatively, the expression of a heterologous PDH complex from 
Enterococcus faecalis was shown to fully complement the cytosolic acetyl-CoA supply in an 
ACS-deficient yeast strain136. Most recently, S. cerevisiae metabolism was successfully 
altered from alcoholic fermentation to lipogenesis metabolism with a high-level production 
of free fatty acids137. All three PDC genes were deleted from an engineered yeast strain with 
improved acetyl-CoA supply. After adaptive laboratory evolution (ALE) in glucose, the 
evolved strain showed that the lipogenesis metabolism could replace the traditional ethanol 
fermentation. A mutated PYK1 was proven to be able to restore the growth of this Pdc-
negative strain in glucose (Fig. 13). Through this mutation, the glycolytic flux was 
downregulated to reduce the high NADH level in the cell.  
Engineering acetyl-CoA metabolism  
The costs of the feedstock can contribute up to 75% of the total costs of the processes for 
producing chemicals of commercial interest from carbohydrates138. This requires maximizing 
the product yields and avoiding carbon loss in order to achieve an economical production 
process. Acetyl-CoA, the essential molecule carrying C2 units in yeast, is a key precursor for 
many metabolites, the acetyl donor for protein acetylation and the fuel for the TCA cycle and 
glyoxylate cycle139,140. In S. cerevisiae, acetyl-CoA is involved in the metabolic network in the 
cytosol, nucleus, peroxisome and mitochondrion, and cannot be transported freely between 
all compartments. As the major substrate for de novo fatty acid synthesis in yeast, the native 
synthesis of cytosolic acetyl-CoA from pyruvate is referred to as the pyruvate-
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dehydrogenase bypass (PDH bypass), in which the AMP-forming ACS catalyzes the last step 
from acetate with the concomitant hydrolysis of ATP to AMP and PPi: 
acetate+ATP+CoA→acetyl-CoA+AMP+PPi 
The formation of acetyl-CoA through the native cytosolic PDH bypass from glucose can be 
described as: 
glucose+4NAD(P)++2ATP+2CoA+2H2O→2acetyl-CoA+2(NAD(P)H+H+)+2CO2+2ADP+2Pi 
Since the native cytosolic PDH bypass pathway is suboptimal in terms of acetyl-CoA supply as 
it results in loss of CO2 and energy, diverse strategies were implemented to benefit the 
process economy of acetyl-CoA synthesis. 
ATP citrate lyase (ACL) is involved in the production of cytosolic acetyl-CoA from citrate and 
is present in oleaginous yeasts such as Yarrowia lipolytica, but not in non-oleaginous yeasts 
such as S. cerevisiae138. ATP is required in the reaction with the formation of ADP instead of 
AMP, resulting in lower energy consumption compared with the native route. Five ACL genes 
from different sources were integrated into the yeast genome to compare their activities, of 
which the ACL from A. nidulans exhibited the highest activity141. Together with other 
modifications, the production of acetyl-CoA derived mevalonate was significantly increased. 
The endogenous mitochondrial citrate transporter Ctp1 was overexpressed to ensure a 
sufficient precursor supply, together with the overexpression of the ACL from Mus musculus, 
malic enzyme from R. toruloides (RtME) and malate dehydrogenase ´Mdh3 (Fig.14), resulting 
an optimized acetyl-CoA pathway with a remarkable improvement in fatty acid production69. 
Another reaction that yields acetyl-CoA from pyruvate is catalyzed by pyruvate-formate 
lyase (PFL) with formate being generated. PFL has to be activated by a PFL-activating enzyme 
(PFL-AE) (Fig. 14). The catalytic activity of PFL depends on a radical residue that makes it 
sensitive to oxygen. Thus, the PFL and PFL-AE from E. coli were first expressed in S. cerevisiae 
to enable a functional replacement of the native PDH bypass as the sole pathway for acetyl-
CoA synthesis during anaerobic culture142 (Fig. 14). In a later study, PFL and PFL-AE from E. 
coli were co-expressed with two different electron donors, reduced ferredoxin or reduced 
flavodoxin, respectively, elucidating that the PFL-driven bypass with these electron donors 
can improve growth of a Pdc-negative strain even under aerobic conditions143. A reversible 
reaction directly from acetaldehyde to acetyl-CoA that yields NADH without consuming ATP 
catalyzed by acetylating acetaldehyde dehydrogenase (A-ALD) was also introduced into S. 
cerevisiae (Fig. 14). Different heterologous A-ALDs were evaluated in a yeast strain with all 
five native ALD genes deleted (ALD2/3/4/5/6∆), showing that all of the candidates enabled a 
faster growth but low final biomass formation142. This phenomenon might be due to the 
acetaldehyde toxicity in the cells. The route towards cytosolic acetyl-CoA synthesis catalyzed 
by phosphoketolase and phosphotransacetylase (XFPK/PTA) has drawn much attention due 
to the complete carbon conversion in the acetyl-CoA formation (Fig. 14). The XFPK enzymes 
can utilize either fructose-6-P (F6P), xylulose-5-P (X5P) or ribulose-5-P (R5P) as substrates. 
The sugar phosphates and inorganic phosphate are converted to acetyl-P and either 
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erythrose-4-P or glyceraldehyde-3-P144. The PTA is responsible for the reaction that converts 
AcP and CoA into acetyl-CoA and Pi. In S. cerevisiae, the co-expression of XFPK from 
Aspergillus nidulans and PTA from Bacillus subtilis was implemented to enhance the 
production of FAEEs significantly145. However, the flux through the XFPK/PTA pathway in 
yeast using glucose as substrate appeared to be low146. As the XFPK/PTA bypass results in a 
negative ATP yield, some carbon has to pass through native glycolysis to promote ATP 
generation, thus preventing complete carbon conversion. 
 
 
Figure 14. Engineering strategies for improving cytosolic acetyl-CoA supply in yeast cells. ME, malic enzyme; 
Mdh, malate dehydrogenase; ACL, ATP citrate lyase; Ald, acetaldehyde dehydrogenase; Acs, acetyl-CoA 
synthetase; Pfl, pyruvate-formate lyase; A-Ald, acetylating acetaldehyde dehydrogenase; Pdh, pyruvate 
dehydrogenase; XFPK, phosphoketolase; PTA, phosphotransacetylase. 
 
3.2 Redox and cofactor engineering 
 
NADH and NADPH are two essential reducing equivalents involved in the conversion of many 
metabolites in yeast, where NADH predominantly participates in catabolic reactions and 
NADPH is mainly required for anabolic reactions. For example, every elongation cycle of fatty 
acid synthesis requires two molecules of NADPH, thus 16 NADPH molecules are needed for 
the formation of one C18 fatty acid. Since yeast cells naturally produce excess NADH as the 
electron carrier, the NADPH supply is usually limiting for the synthesis of fatty acids and its 
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derivatives. NADPH is predominantly generated from the pentose phosphate pathway (PPP) 
in yeast (Fig. 15). The pathway is initiated by oxidizing G6P via glucose-6-phosphate 
dehydrogenase (G6PDH, encoded by ZWF1), which is the first rate-limiting step in the PPP. 
Then, ribulose-5-phosphate is generated through 6-phosphogluconate dehydrogenase 
(6PGDH, encoded by GND1 and GND2), thereby yielding two molecules of NADPH. Many 
attempts in metabolic engineering have been made to increase the NADPH supply in the 
cytosol. In the recent study for improved fatty acid production, extra NADPH was produced 
by overexpression of the otherwise mitochondrial malic enzyme (Fig. 14), which converts 
malate into pyruvate, in the cytosol69. 
 
 
Figure 15. An overview of NADPH synthesis in yeast and engineering strategy for improved NADPH production. 
GAPN, glyceraldehyde-3-phosphate dehydrogenase; TKL1, transketolase; TAL1, transaldolase; ZWF1, glucose-6-
phosphate dehydrogenase; GND1/2, 6-phosphogluconate dehydrogenase. 
In order to facilitate NADPH regeneration and reduce the loss of carbon, a non-
phosphorylating NADP+-dependent glyceraldehyde-3-phospate dehydrogenase (GAPN) from 
Bacillus cereus was expressed in a yeast strain with deletion of GPD1 encoding NAD+-
dependent glycerol-3-phosphate dehydrogenase147 (Fig. 15). In previous work from our 
group, fine tuning the flux distribution between the PPP and glycolysis by overexpression of 
the GND1 gene, transketolase (encoded by TKL1) and transaldolase (encoded by TAL1), 
together with downregulation of phosphoglucose isomerase (encoded by PGI1) in yeast to 
provide additional NADPH led to a 28% increase in free fatty acid production137. 
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3.3 Protein engineering 
 
Enzymes are considered as versatile biocatalysts catalyzing diverse chemical reactions in 
nature, and evolution has enabled them to possess high activities and high specificities 
towards challenging substrates. Protein engineering is a process with the goal of obtaining 
modified enzymes that are more suitable for a particular application or purpose than the 
unmodified enzymes, which generally follows two main strategies, the random approach or 
the rational design. Both can also be combined in a semi-rational design strategy148. 
Random approach (Paper III & IV) 
The random approach referred to as directed evolution is mainly conducted by introducing 
random mutations into either a single protein sequence or the sequence encoding the active 
site coupled to high-throughput screening and selection strategies. Screening and selection 
are two of the most important procedures involved in protein engineering, of which the 
selection process could automatically eliminate less-functional variants, while the screening 
facilitates the evaluation of each protein for the desired property149. Directed evolution can 
be conceptualized as series of mutational steps in a fitness landscape that represents the 
phenotype of all the variants in the library. The goal of directed evolution studies is to take 
these steps within the fitness landscape that “climb” towards peak activity levels, during 
which the beneficial mutations will result in a successively improved pheotype150. Various 
information including 3D structure information of the target protein is unnecessary, which is 
one of the advantages of the random approach (Fig. 16). Theoretically, this means that the 
approach could be applied towards any protein. 
 
Figure 16. The features of different protein engineering methods in terms of the sizes of the library and the 
amount of information required. Adapted from Romas et al. and Liu et al. 151,152.  
Before performing directed evolution, the library creation is the first crucial step, since the 
diversity of library affects the exploration of a protein’s potential properties. Methods for 
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the library construction have been developed in recent years, such as error-prone PCR and 
DNA shuffling. Error-prone PCR is the most commonly used way to create genetic variation 
nowadays, during which the gene is amplified in the presence of manganese ions or 
nucleotide analogs to promote mutagenesis through the DNA polymerase or by using a low 
fidelity DNA polymerase153. In the laboratory, the level of mutagenesis can be controlled by 
the concentration of template and the number of reaction cycles154. DNA-shuffling is widely 
applied to effectively recombine homologous genes from different species, which requires 
high similarity of the DNA sequences of multiple parent genes155,156. However, it is still 
impossible to cover the entire mutational space of a typical protein with all known library 
creation methods, as approximately 1013 unique mutants are required for a complete 
randomization of a mere decapeptide150.  
In order to obtain an improved phenotype through the random approach, several rounds of 
evolution usually have to be conducted, which is time- and labor-consuming. In addition, as 
the library size is relatively large, a convenient and efficient high-throughput screening 
method is required to benefit the accumulation of beneficial variants that would greatly 
reduce the chance of missing the desired mutant (Fig. 16). For example, fluorescent proteins 
that possess a screenable phenotype, such as GFP, have been widely used in directed 
evolution by fusion the GFP protein to the enzyme of interest; the enzymes with improved 
solubility or folding related to the florescence signal will thus be easily visualized by 
fluorescent microscopy157,158. Recently, the directed evolution strategy was also applied to 
benefit biofuel production. Variants of the AcrB efflux pump from E. coli that act on the non-
native substrate n-butanol were generated and selected through this random approach. 
These variants conferred an improvement of the tolerance to n-butanol, resulting in 
enhanced growth rates of E. coli by up to 25%159. And a cellodextrin transporter CDT2 was 
engineered in S. cerevisiae under anaerobic conditions through directed evolution; a 
significant improvement of cellobiose uptake activity and ethanol productivity was observed 
after several rounds of evolution160. 
As the current production of MCFAs by yeast cells has already approached the inhibitory 
concentration that is around 1 mM for octanoic acid and decanoic acid161,162, it is challenging 
to enable further accumulation of medium-chain fatty acids (MCFAs) in yeast, which makes it 
urgent to mitigate the toxicity for the cells. In Paper III, we evolved a native membrane 
efflux pump Tpo1 to increase its activity conferring cellular resistance against C10 fatty acid. 
Since the detailed mechanisms and structure information of Tpo1 are not known, we 
performed the random approach to engineer this protein.  
Tpo1 was originally identified as a polyamide transporter that is located on the plasma 
membrane163, and it was observed to benefit the resistance of yeast cells against diverse 
toxic compounds, such as decanoic acid164. To investigate the function of Tpo1 in yeast, we 
sought to cultivate the Tpo1 negative strain in medium with 50 mg/L of decanoic acid, which 
led to impaired growth in such toxic medium. Overexpression of Tpo1 from a single-copy 
plasmid under the control of the TDH3 promoter restored the resistance against decanoic 
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acid (Fig. 17a). We then sought to use directed evolution to obtain a better Tpo1 variant 
which could enable the yeast cells to have improved tolerance against decanoic acid (Fig. 
17b).  
 
Figure 17. The design of Tpo1 transporter engineering. (a) The role of Tpo1 involved in cellular tolerance 
against decanoic acid. The CEN.PK 113-5D, 5D strain with Tpo1 deletion, Tpo1 deletion strains with empty 
plasmid (EP) or TPO1 overexpression plasmid were tested in medium with different concentration of decanoic 
acid. The final OD600 was measured after 72 h in CSM media with decanoic acid as indicated. (b) The overview 
of the directed evolution process. Adapted from Paper III. 
A random mutagenesis library was created through error-prone PCR with a library size of ~7.8 × 104 mutants, and three Tpo1 mutants (M11, M21 and M41) were selected after 
enrichment in medium with 60-90 mg/L of decanoic acid (Fig. 18 and see Supplementary 
Figure S7a in Paper III). The mutagenesis library for the second round of evolution was 
established based on the best variant M21 from the first round, then the best variant M49 
with an improved activity was obtained from the screening with higher decanoic acid 
concentration (90-100 mg/L) (Fig. 18 and see Supplementary Figure S7b in Paper III). 
 
 
 
Figure 18. The positions of each mutation in Tpo1 variants M11, M21, M41 and M49. Adapted from Paper III.  
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The growth of yeast strains containing M49 (F322L, T54S, I432N) and M21 (F322L) was 
tested in medium with decanoic acid, showing that growth of both of the strains was 
significantly improved compared with the strain carrying the wild type Tpo1 (Fig. 19a). We 
then investigated the contribution of each mutation individually, the results also showed 
that mutation F322L conferred the major contribution to the observed phenotype (see 
Supplementary Figure S7c in Paper III). Normally, an improved tolerance could in turn 
benefit the production of the corresponding chemicals. Thus, we integrated the expression 
cassettes of wild type TPO1 and the M49 mutant independently into chromosome of stain 
YHE02 with POX1 and TPO1 deleted to investigate if the evolved Tpo1 could improve the 
production of MCFAs, and the two strains were transformed with the MCFA production 
plasmid pScFAS28. The titer of extracellular fatty acids had significantly increased in the 
strain expressing M49, and each species of MCFAs, especially C10 to C14, was enhanced by 
19% to 213% compared to the strain containing wild-type Tpo1 (Fig. 19b). We then 
introduced two copies of M49 into strain YHE02 to investigate if the production of MCFAs 
could be further improved. According to the results, the final titer of extracellular fatty acids 
reached 110 mg/L, and the titers of each MCFA species increased by 79-320% (Fig. 19b and 
Supplementary Figure S8a in Paper III). Owing to the poor understanding of these major 
facilitator superfamily (MFS) transporters, the functions of the altered amino acid residues 
were difficult to deduce. However, we successfully obtained a more efficient Tpo1 
transporter to enhance the final titer of MCFAs in this work, which demonstrated that 
directed evolution-based transporter engineering could be a promising strategy to elevate 
the production of toxic chemicals resulting from improved cellular tolerance.  
 
Figure 19. The effect of engineered Tpo1 on cellular tolerance and the production of MCFAs. (a)The growth 
curves of the strains YHE02 (pox1Δ & tpo1Δ) expressing Tpo1 variants M21, M49 and wild-type Tpo1 in CSM-
URA medium with 100 mg/L decanoic acid. The cell densities were measured by Biolector. (b) The profile of 
MCFAs produced by strains containing wild-type Tpo1, one copy of M49 and two copies of M49 in the 
chromosomes. MCFA production plasmid pScFA28 was introduced as well. Adapted from Paper III. 
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In Paper IV, we focused on engineering a carboxylic acid reductase from Mycobacterium 
marinum (MmCAR), which is a key enzyme involved in fatty aldehyde production from fatty 
acids. Fatty aldehydes are the common precursors for different oleochemicals, such as fatty 
alcohols and alka(e)nes. The CAR enzyme consists of an adenylation domain (A domain) and 
a reductase domain (R domain) linked via a peptidyl carrier protein (PCP). The 
conformational dynamics of the CAR enzyme can be conferred with different nucleotide 
ligands, where the ATP-bound form represents the adenylation state, and AMP or AMP-acyl 
bound forms are always observed in the thiolation state165. In this work, in order to enable a 
selective medium-chain fatty alcohol (MCFOH) synthesis, we designed multiple strategies for 
multidimensional engineering of MmCAR, including a random approach via directed 
evolution, and structure-guided semi-rational design and rational approaches. 
 
 
Figure 20. The design of a high-throughput screening approach for MmCAR variants. (a) Comparison of the 
cellular toxicity of MCFAs and the corresponding fatty alcohols. Strain YJZ03 (Δpox1 Δhfd1) was used to 
evaluate the toxicity by measuring the final OD600 of the strain cultivated in equivalent concentrations of 
MCFAs/MCFOHs for 72 h. (b) The final OD600 of strains with/without MmCAR after cultivation in 1mM C8 fatty 
acid (c) The workflow of the high-throughput growth-coupled enzyme engineering method. Adapted from 
Paper IV. 
To improve the catalytic function of MmCAR for MCFA conversion, directed evolution was 
performed by first establishing a random mutagenesis library of the full-length MmCAR. 
Meanwhile, an efficient growth-coupled screening approach was created to assist the 
selection of MmCAR variants. As mentioned above, MCFAs are toxic to yeast cells, thus the 
toxicity could be utilized for the selection of enzyme variants related to their capacities of 
detoxification. We thus compared the toxicity of octanoic acid and decanoic acid and their 
corresponding fatty alcohols using strain YJZ03 with the deficiency of Pox1 and Hfd1. 
According to the results, equal toxicity to the cells was observed for the same concentration 
(70 mg/L) of C10 fatty acid and fatty alcohol, and distinct toxicity to the cells was observed 
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for the same concentration (150 mg/L) of C8 fatty acid and C8 fatty alcohol, where the C8 
fatty acid showed much more toxicity to the cells than C8 fatty alcohol (Fig. 20a). Therefore, 
1mM (150 mg/L) C8 fatty acid was used to investigate if the conversion from MCFAs to 
MCFOHs by MmCAR could be a potential detoxification pathway for MCFAs. The final OD600 
of the strain containing MmCAR was much higher than the control strain in the presence of a 
high concentration of C8 fatty acid, suggesting that the expression of MmCAR benefits MCFA 
detoxification through formation of less toxic MCFOHs (Fig. 20b). Thus, a growth-coupled 
high-throughput screening scheme was established based on the detoxification of C8 fatty 
acid, where enzyme variants with a higher activity catalyzing the MCFA reduction can be 
selected (Fig. 20c).  
 
Figure 21. The synthesis of MCFOHs in S. cerevisiae expressing MmCAR variants. (a) Schematic illustration of 
the mutated MmCARs derived from two rounds of directed evolution based on the full-length MmCAR. (b) 
Production of MCFOHs in S. cerevisiae expressing mutated MmCARs derived from directed evolution based on 
full-length MmCAR. Adapted from Paper IV. 
Using this efficient screening method, an increasing concentration of C8 FA from 290-330 
mg/L was used to facilitate the variant selection for the first round of evolution based on 
random mutagenesis of the full-length MmCAR. The beneficial variant CAR*-M150 was 
isolated from the first round, whose expression enabled the best growth of yeast cells in 
medium with C8 fatty acids. In this mutant, two of the mutations D241E and H454R, were 
located in A domain of MmCAR, while the mutation L567M was located between A domain 
and PCP domain (Fig. 21a). Subsequently, the plasmid CAR*-M150 was extracted from YJZ03 
and introduced into the high MCFA producing strain ZWE243 to test the production of 
MCFOHs. The results showed that CAR*-M150 enabled a titer of 120 mg/L MCFOHs, which 
was a more than 50% increase in MCFOH production compared with the wild type MmCAR 
(Fig. 21b). The CAR*-M150 was therefore used as the template to establish a mutagenesis 
library for the second round of evolution, during which a higher concentration of C8 FA 
(330–370 mg/L) was utilized for the library enrichment. From the second round of evolution, 
the variants CAR*-M7, CAR*-M9 and CAR*-M11 were selected as the most efficient mutants 
based on the cell growth. Their expression in strain ZWE243 also enabled the production of 
around 100 mg/L, 40 mg/L and 110 mg/L of MCFOHs, respectively (Fig. 21b). We identified 
a
MmCAR-wt
88 541 651 726 731 1174
CAR*-M150
D241E
H454R
L567M
F933Y
D241E H454R L567M
Q151R M293L
CAR*-M7
D241E
H454R
L567M
D879NE566D
D482V
CAR*-M9
D241E
H454R
L567MP161H
A184S S643T H750R
K808N
P834L
CAR*-M11
0M
ed
iu
m
 c
ha
in
 fa
tty
 a
lc
oh
ol
s 
(m
g/
L)
60
20
40
80
100
120
140
CA
R*
-M
7
CA
R*
-M
9
CA
R*
-M
11
CA
R*
-M
15
0
pZ
W
MA
OH
01
b
C12
C10
C8
C6
A domain PCP R domain
 37 
 
several beneficial mutants based on directed evolution of the full-length MmCAR that 
potentially enhanced the catalytic activity towards MCFAs. Although strains expressing the 
three variants could not produce as many MCFOHs as the strain expressing M150, two of the 
variants still showed higher catalytic activity towards MCFA conversion compared to the wild 
type as more MCFOHs were produced in vivo (Fig. 21b). Two of the mutated residues 
(D241E, H454R) from M150 appeared on the surface of the A domain rather than the active 
site, and the other one (L567M) located on the Asub domain for which the conformation 
changes substantially between the adenylation and thiolation state, which indicated that 
these mutations affected the activity of MmCAR indirectly (see supplementary Figure S8).  
Rational approach and semi-rational approach (Paper III & IV) 
With the advances in acquiring protein structures or reliable models, biochemical data and 
computational methods, protein engineering is developing more and more from random 
approaches to data-driven rational or semi-rational design166. Rather than selecting from 
bigger libraries through repeated screening processes, many studies are moving beyond 
traditional directed evolution, instead advocating new strategies for designing smaller (Fig. 
16), higher quality libraries167. In a rational or semi-rational approach, the focus on specific 
amino acid residues inferred from these reliable data significantly reduces the library size, 
which results in libraries with higher functional content (Fig. 16). Thus, less efforts and time 
have to be applied for screening of the library and this is especially advantageous if no high-
throughput assay system is available. However, an in-depth understanding of the structural 
features of the active site and their functions is highly required for rational design (Fig. 16), 
which imposes restrictions on its general application168,169. On the other hand, semi-rational 
design, such as site saturation mutagenesis, could target multiple residues based on the in 
silico prediction and sequence information (Fig. 16), which can lead to the identification of 
the potentially crucial residues170,171. Sequence-guided enzyme redesign, performed by 
multiple sequence alignments (MSA), is the most popular strategy, which enables the 
exploration of amino acid conservation and evolutionary history among homologous protein 
sequences and structures172. Based on the sequence homology, it is beneficial for protein 
engineering in identifying functional hotspots, assessing local amino acid variability and 
guiding back-to-consensus design167,172. The development of protein structure databases and 
homology modeling offer valuable assistance for structure-based enzyme redesign. More 
specific residues located near the key active sites and domain interfaces could be identified 
to benefit an efficient superior library design. For example, Cahn and co-workers established 
a structure-guided, semi-rational strategy for reversing enzymatic nicotinamide cofactor 
specificity173. The efficacy of this strategy was demonstrated by inverting the cofactor 
specificity of four structurally diverse NADP-dependent enzymes towards NAD. Recently, 
computational enzyme redesign has become a promising strategy due to the development 
of in silico modeling. The advanced computational method can efficiently estimate the 
energetics of amino acid variation on the overall protein structure with the advantage of 
reducing experimental protein engineering to the evaluation of only a handful of rational 
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designs167. Chen and co-workers reported a computational, structure-based redesign to 
switch the substrate specificity of the phenylalanine adenylation domain in the 
nonribosomal peptide synthetase enzyme gramicidin S synthetase A174. Furthermore, a 
computational method was also applied to reconstruct a critical loop in human guanine 
deaminase to enable a 100-fold increase of enzyme activity towards ammelide175. Besides 
the random approaches mentioned above, also rational and semi-rational strategies were 
implemented in our work to enable an improved enzyme activity. 
The fungal FASI (fFASI) was engineered by embedding thioesterases into the reaction 
chamber to release MCFAs in our previous study60. Due to the high similarity between 
bacterial FASI (bFASI) and fFASI, we assumed that the same engineering strategies could also 
be applied to bFASI for changing the chain length of fatty acid products. In Paper III, we 
performed rational design to both of a bFASI (from Mycobacterium vaccae, MvFAS) and 
fFASI (from S. cerevisiae, ScFAS), resulting high-level production of MCFAs through the co-
expression of these FAS variants.  
 
Figure 22. The synthesis of MCFAs in strains with engineered fFASI enzymes. (a) Overview of domain 
composition of the FASI enzymes from S. cerevisiae and M. vaccae. (b) Schematic overview of engineered fFASI. 
(c) The production of extracellular MCFAs by strains containing plasmids encoding engineered fFASI. (d) The 
production of extracellular MCFAs by strains with engineered fFASI genes integrated. Adapted from Paper III. 
In the previous study, the incorporation of a heterologous short-chain thioesterase enabled 
the production of MCFAs176. We therefore evaluated different heterologous thioesterases in 
S. cerevisiae FAS (ScFAS15), among which the ‘AcTesA from Acinetobacter baylyi was found 
to be the most efficient short-chain thioesterase (see Supplementary Figure S2 in Paper III). 
A mutated KS domain (equivalent to G1250S and M1251W in Fas2) was reported to confer 
steric restriction against long-chain acyl-ACP, and mutations in the AT and MPT domain 
(equivalent to I306A and R1834K in Fas1) could alter the substrate loading as well as acyl-
CoA offloading efficiency59,177. Different combinations of mutated KS domain, AT domain and 
MPT domain were constructed based on wild type ScFAS (Fig. 22b). ScFAS05 only containing 
mutated KS was found to be the most efficient variant, in which the ‘AcTesA thioesterase 
was introduced to generate ScFAS28 (Fig. 22c). The integration of ScFAS28 in ZW207 
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resulted in the production of 85 mg/L MCFAs, 45% higher than those produced by the strain 
with only the mutated KS domain, and 143% higher than those produced by ZW206 
containing the FAS only with the ‘AcTesA thioesterase (Fig. 22d).  
Different from fFASI, the type I FASs from the CMN (Corynebacteria, Mycobacteria and 
Nocardia) group of Actinobacteria are single-chain proteins with an auxiliary 
phosphopantetheinyl transferase (AcpS in the bacterial FAS system)178. As bFASI is highly 
similar to fFASI (Fig. 22a), and the expression of bFASI in yeast is not subjected to 
endogenous regulations179, it would be interesting to introduce bFASI for MCFA production. 
In our work, a strategy equivalent to the one used for fFASI was applied to improve the 
activity of bFASI from M. vaccae towards production of MCFAs successfully. The co-
expression of engineered bFASI and fFASI further increases in the production of MCFAs (see 
Figure 1h and i in Paper III).  
In conclusion, the expression of two engineered FASI systems in yeast significantly facilitated 
the production of MCFAs, which also revealed that the engineering strategy for the FASI 
enzyme is applicable to variants from distant species.  
For the downstream MCFOHs production, further rational and semi-rational redesign of 
MmCAR was conducted based on its distinct domains in Paper IV. As MmCAR possesses a 
broad substrate spectrum ranging from C4 to C18, which is suboptimal for MCFOH 
production, we sought to change the substrate specificity towards MCFAs through narrowing 
down the substrate binding pocket. The A domain of CAR exhibits a mechanism of substrate 
identification and activation similar to that of the ANL superfamily of adenylation enzymes, 
where the ATP is attacked by the oxygen from the carboxylic acid to generate an AMP-acyl 
phosphoester180–182. Enzymes from the superfamily of acyl-activating enzymes (AAEs), such 
as fatty acyl-AMP ligases (FAALs) and fatty acyl-CoA ligases (FACLs), are able to transfer the 
carboxylic groups of their substrates to other acceptor groups, suggesting that they share a 
function similar to the A domain of CAR181,183. A potentially crucial residue S306 (I303 in 
MmCAR) was identified after aligning the FAAL from E. coli (PDB id 3PBK) with the A domain 
of CAR from Nocardia iowensis (NiCAR PDB id 5MSD) (Fig. 23c). In a previous study, a bulk 
tryptophan was introduced to result in mutated proteins FAAL28 (I227W) and FACL13 
(T214W) in the respective enzymes from Mycobacterium tuberculosis at the position 
equivalent to Q302 in MmCAR (I305 in NiCAR). The mutated enzymes had a significant 
increase in the activity towards C10 or C8 fatty acids, respectively, rather than longer acyl 
chains183. We thus replaced the amino acids of residues I303 and Q302 in MmCAR with a 
tryptophan. The variants containing I303W and Q302W enabled ~130 mg/L and ~110 mg/L 
of MCFOHs, respectively (Fig. 23a and b). According to the results, we speculated that the 
catalytic pocket of MmCAR was narrowed resulting from steric hindrance caused by the 
introduction of the bulkier tryptophan. Meanwhile, we also performed directed evolution 
towards the A domain of MmCAR coupled with the high-throughput screening method 
described above (Fig. 20c). After two rounds of evolution, CAR*-A69 from the first round and 
CAR*-A10 from the second round were isolated and expressed in high MCFA producing 
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strain ZWE243, both resulted in around 100 mg/L of MCFOHs (Fig. 23b). More C6 and C8 
fatty alcohols were produced by the CAR*-A10 containing strain compared with CAR*-A69 
strain. Four mutations (E176G, Q182R, Q371R, F501Y) were identified in the efficient variant 
CAR*-A10. However, all of them located on the surface of the A domain instead of the 
binding pocket. The distinct catalytic activities of the mutants derived from these 
approaches indicated that the rational design interfering with the binding pocket directly 
was potentially more efficient than the random approach in terms of altering substrate 
specificity. 
 
Figure 23. The synthesis of MCFOHs in S. cerevisiae by different MmCAR mutants. (a) Schematic overview of 
MmCAR mutants derived from different strategies. (b, e) Production of MCFOHs in S. cerevisiae by mutated 
MmCARs derived from adenylation domain modification (b) and reductase domain optimization (e). (c) 
Assignation of the amino acid residue related to the substrate chain length determination. And the alignment 
of sequences of FAALs and CARs are presented (d) The on- and off-states of the R domain determined by the 
conformational change of C983-M985. Adapted from Paper IV. 
The R domain of MmCAR is where the thioester is reduced using NADPH; it enables a strict 
two-electron reduction of the acyl-PCP thioester to a fatty aldehyde. However, the backbone 
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reorientation of residues 983-985 was reported to affect the conformational equilibrium 
between on- and off-states of the MmCAR R domain towards a more efficient four-electron 
reduction184. The D984 will be positioned away from the nicotinamide in the active form, 
while it will locate with the nicotinamide binding pocket in the inactive form together with 
S983 (Fig. 23d). We introduced the mutations D984G and M985A into MmCAR individually 
with the aim to potentially change the final product to fatty alcohols as previously 
reported184. However, both mutants showed a negative effect on MCFOH production in 
yeast (see Supplementary Figure S3b and S3c in Paper IV). As our high-throughput screening 
approach was very effective for selection of enzyme variants from different mutagenesis 
libraries, in order to obtain an engineered R domain free of conformational regulation by 
C983-M985 or more efficient for reduction of medium-chain substrates, we applied this 
method for screening of a site-directed saturation mutagenesis library targeting residues 
983-985 (Fig. 23a). Four variants (CAR*-F1/E5/E6/B6) that enabled a higher growth rate and 
final OD of yeast cells in the medium with 380 mg/L C8 FA were isolated and introduced into 
ZWE243 to investigate if they are also beneficial for MCFOH production (see Supplementary 
Figure S4 in Paper IV). Consistently, all these variants showed positive effects in MCFOH 
production, among which the CAR*-F1 (C983P, D984H, M985L) was the most efficient one 
that led to a final production of 170 mg/L MCFOHs (Fig. 22e). A common mutation (M985L or 
M985I) was found among these four MmCAR variants (Fig. 23a). However, after determining 
MCFOH production in a strain containing the individual mutation (CAR*-M985L), we found 
that the M985L mutant only led to a production of around 100 mg/L MCFOHs in yeast (see 
Supplementary Figure S5 in Paper IV). Meanwhile, the CAR*-F1w/o985 variant containing 
only the other mutations (C983P and D984H) from CAR*-F1 was also constructed and tested 
in strain ZWE243. The results showed an even slightly stronger effect on MCFOH production 
than for the CAR*-F1 mutant, indicating that these two mutations rather than M985L might 
play a more critical role in CAR*-F1 for MCFOHs production.  
 
Figure 24. The synthesis of MCFOHs in S. cerevisiae by MmCAR chimeras with two PCP-R domains. (a) 
Schematic overview of MmCAR chimeras with two PCP-R domains are presented. CAR*-RS01, CAR*-RS02 and 
CAR*-RS03 are plasmids containing MmCAR separately co-expressed with RNRP, RMxaA and RGPL, respectively. 
CAR*-RS011, CAR*-RS021 and CAR*-RS031 are plasmids containing MmCAR fused with RNRP, RMxaA and RGPL 
using linker GGGGS, respectively (b) The production of MCFOHs in S. cerevisiae by MmCAR variants with di-
domain. Adapted from Paper IV. 
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In a previous study, the comparison based on crystal structures between MmCAR and 
nonribosomal peptide synthetases (NRPSs) elucidated that they share a high similarity in the 
structures of the reductase domains185,186. We selected three reductase domains sharing 
high identity (50%) with the MmCAR R domain from a glycopeptidolipid (GPL) cluster of 
Mycobacterium smegmatis (RGPL), an NRPS of Mycobacterium tuberculosis (RNRP) and a 
terminal NRPS module (MxaA) of Stimatella aurantiaca Sga15 (RMxaA) that had been reported 
to catalyze the 4-electron reduction to replace the native MmCAR R domain, respectively. All 
the chimeras, however, seem to have lost their function as no MCFOHs were detected in the 
yeast strains (data not shown). Instead, the heterologous PCP-R domains were introduced 
into yeast as shown in Figure 24a through either fusion with MmCAR using linker GGGGS or 
separate expression together with MmCAR in the cells to avoid misfolding of MmCAR. 
Surprisingly, most of the chimeras had positive effects on the MCFOHs production in yeast, 
of which the best variant CAR*-RS011 (MmCAR fused to the RNRP) enabled around 150 mg/L 
of MCFOH production (Fig. 24b). 
 
Figure 25. The substrate specificity of MmCAR mutants was characterized in vivo. (a) GC spectrum of 
intracellular fatty alcohols derived from strains ZWE243 with wild type CAR, CAR*-M150, CAR*-A303 and CAR*-
F1, respectively. (b) Profiles of intracellular fatty alcohols in strain containing wild-type MmCAR, CAR*-M150, 
CAR*-A303 and CAR*-F1, respectively. Adapted from Paper IV. 
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Although the increase in production of MCFAs was achieved in those chimeras integrated 
with 4-electron R domains, it remained impossible to determine whether this enabled direct 
production of alcohols in vivo. In this part of the work, we have applied both rational and 
semi-rational design towards the R domain of MmCAR. The results elucidated that the 
smaller mutagenesis library from a semi-rational redesign led to a more efficient and direct 
effect on the desired function. Both of the approaches represent a less time-consuming and 
high efficiency manner compared with random approaches.  
Besides assessing the production of total MCFOHs in yeast strains, we evaluated the 
substrate specificity of MmCAR mutants towards distinct chain-lengths of fatty acids in vivo 
and in vitro as well. We determined the intracellular fatty alcohols derived from strains 
containing the wild-type MmCAR, CAR*-A303, CAR*-M150 and CAR*-F1, respectively. Based 
on the GC spectra, we could clearly see that the major components of intracellular fatty 
alcohols were MCFOHs (C8-C12) and relatively less long chain fatty alcohols (LCFOHs, C14-
C16) were detected (Fig. 25a). After comparing the ratio of each component, all the MmCAR 
variants enabled a higher proportion of MCFAs compared to the wild type. 75%, 78% and 
67% of MCFOHs were produced by the strains containing CAR*-A303, CAR*-F1 and CAR*-
M150, respectively, and the wild-type MmCAR had only 59% of MCFOHs (Fig. 25b). 
Furthermore, the activities for reducing fatty acids with different chain length were 
measured in crude protein extracts. According to the results, the activities towards C6-C10 
fatty acids were improved in the presence of all the mutants compared to the wild type, 
except for the comparable activity of M150 on C10 fatty acids (Fig. 26). The I303W mutant 
seems the most efficient one that enabled about 2-fold increase in the activity towards C6 
fatty acid compared to the wild type.  
 
 
Figure 26. The substrate specificity of MmCAR mutants was characterized in vitro. The NADPH oxidation rate of 
the crude protein extracted from strain ZWE243 containing CAR*-F1, CAR*-M150, CAR*-A303, the wild-type 
MmCAR and an empty plasmid, respectively. Adapted from Paper IV. 
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27a). The polyamine exporter Tpo1 had been reported to confer tolerance against MCFAs, 
and according to our previous work, an engineered Tpo1 was able to benefit the cellular 
tolerance against C10 and C8 fatty acid as well as the production of MCFAs. We therefore 
speculated that the deletion of it would potentially enable a further increase in MCFOH 
production through reducing the secretion of MCFAs. Thus, we deleted TPO1 from yeast 
strain ZWE243, yielding YH28. Three plasmids pZWMAOH01, CAR*-A303, CAR*-F1+303 
leading to distinct amounts of MCFOHs being produced were introduced into ZWE243 and 
YH28, respectively. The results showed that the improvement of MCFOH production was 
only observed in the Tpo1 deletion strain containing the most efficient variant CAR*-F1+303, 
for which 250 mg/L of MCFOHs were obtained with a 3-fold increase compared with the 
original strain (Fig. 27b). This suggested that the flux could only be redirected towards the 
MCFOH production by the variant with highest activity of MCFAs conversion in the TPO1 
deletion strain. Although the mechanistic details of how Tpo1 benefits the tolerance against 
MCFAs are still not fully clear, the possible mechanism inferred from our results in this work 
and previous work could be that Tpo1 might provide a channel for exporting the toxic 
substrates and the channel would be blocked in the absence of Tpo1. 
  
 
Figure 27. The synthesis of MCFOHs in strains with different combined mutants and TPO1 deletion. (a) The 
production of MCFOHs in the ZWE243 strains containing plasmids pZWMAOH01, CAR*-M150, CAR*-A303, 
CAR*-M150+303, CAR*-F1w/o985, CAR*-F1w/o985+303, CAR*-RS011, CAR*-RS011+303, CAR*-F1 and CAR*-
F1+303, respectively. (b) The effect of TPO1 deletion on the MCFOH production. Adapted from Paper IV. 
In conclusion, we implemented diverse protein engineering strategies to enable a significant 
improvement in the production of MCFAs and MCFOHs in S. cerevisiae. Here, protein 
engineering was applied to benefit the crucial catalytic reactions through optimizing the key 
enzymes as well as to improve product tolerance through modifying membrane 
transporters. 
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3.4 Adaptive laboratory evolution 
 
Adaptive laboratory evolution (ALE) is a frequently used strategy for engineering 
microorganisms through accessing the basic mechanisms of molecular evolution and 
adaptive changes after long term selection under harsh growth conditions. Different from 
the protein engineering strategies mentioned above, ALE allows nonintuitive beneficial 
mutations to occur in diverse genes and regulatory regions in parallel187,188. Owing to the 
advances in next-generation sequencing technologies in recent years, ALE has been 
successfully applied to facilitate the establishment of production platforms for many 
organisms, such as S. cerevisiae and E. coli. 
For instance, a high concentration of ethanol has been proven to result in cell wall instability 
and cell lysis189,190. Adaptation of a xylose-utilizing genetically engineered yeast strain to 
sugarcane bagasse hydrolysates improved multiple-inhibitor tolerance, while the ethanol 
yield in the adapted strain was improved 1.11-fold. Analysis of the evolved strain suggested 
a rearrangement in the composition of the cell wall190,191. A high concentration of organic 
acids, such as acetic acid, succinic acid and lactic acid, was observed to negatively affect the 
cell growth of yeast and E. coli192–194. A continuous culture was performed with a wild type E. 
coli strain in a gradually increasing concentration of succinate. The evolved strain was able to 
produce and sustain significantly higher titers of succinate (0.5 M) after the ALE. Reverse 
metabolic engineering was thus performed after identifying potentially beneficial mutations 
through DNA microarray analysis, and greater growth rates for the reverse engineered 
strains were observed under 0.592 M succinate stress conditions than for the wild-type192. In 
general, it would be beneficial for fermentations using yeast to conduct these at ≥ 40 °C in 
terms of increasing efficiency of the process and reducing costs. Therefore, ALE successfully 
facilitated the selection of yeast strains with improved growth and ethanol production at ≥ 
40 °C195. Moreover, the underlying mechanism was revealed after genome sequencing, 
where a sterol composition change was found to contribute to this phenotype. In these 
successful examples, the potential of ALE in biotechnological engineering as a promising 
approach was highlighted. In our work, ALE was also implemented to improve the cell fitness 
against octanoic acid in order to benefit MCFA production in yeast.  
In Paper III, the cellular resistance against decanoic acid was successfully improved through 
engineering the Tpo1 transporter, which was demonstrated to be beneficial for MCFA 
production. Therefore, we assumed that an improved cell fitness against these toxic 
chemicals could also be achieved by ALE. The ALE experiment was implemented to achieve 
improved MCFA tolerance through cultivation of a yeast strain in medium with octanoic acid. 
Thus, YJZ02 (Δpox1) as the parent strain was used for ALE, which has the advantage of 
preventing cells acquiring improved tolerance through an increased MCFA degradation 
activity. In order to perform ALE, cells were continuously transferred to fresh medium with 
octanoic acid for more than 100 generations (Fig. 28). We harvested the evolved strains with 
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significantly improved tolerance against octanoic acid from different stages during the 
evolution process, and seven protein-encoding genes were found having mutations after 
sequencing the genomes of three evolved strains (Fig. 28).  
A M1I mutation at the start codon of PDR1 that encodes a transcription factor regulating 
multidrug resistance genes was identified in ZWE01.29, and this mutation was passed down 
to the later isolated clones (Fig. 28, see Supplementary Figure S10 in Paper III). One 
nonsense mutation Y1142* was discovered in the pleiotropic ABC efflux transporter Pdr5 
that is regulated by Pdr1 in ZWE03. A similar phenotype of conferring cellular tolerance 
against octanoic acid was enabled by the mutated PDR1 allele (Pdr1, M1I) and other alleles 
(Pdr1, M1*; Pdr1, ΔN181; and Δpdr1), demonstrating that the mutated Pdr1 (Pdr1, M1I) was 
a null mutant (see Supplementary Figure S11 in Paper III). Osh2 has been reported to 
transport sterols between organelle membranes196. A frameshift mutation and a substitution 
mutation D1206Y in Osh2 were found in ZWE01.8 and ZWE01.29 of the ZWE01 population, 
respectively (Fig 28, see Supplementary Figure S10 in Paper III). According to the structure 
analysis, these two mutations in Osh2 might result in the loss-of-function of Osh2 (see 
Supplementary Figure S12 in Paper III). 
 
 
Figure 28. The ALE procedure for obtaining octanoic acid resistant strains. 
To investigate if the deletion of both OSH2 and PDR1 in the original strain could lead to 
improved resistance to octanoic acid as well a comparison of cell growth in 400 mg/L 
octanoic acid was conducted for different strains. The results showed that the deletion of 
both OSH2 and PDR1 in strain YJZ02 had an effect similar to the final evolved strain ZWE03 
on the level of resistance against octanoic acid (Fig. 29).  
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Figure 29. Growth comparison of evolved strain, parental strain and strains with PDR1 and/or OSH2 deletion. 
Afterwards, the plasmid ScFAS28 was introduced into the evolved strains to evaluate the 
performance concerning MCFA production, and we found that they were able to produce 
more MCFAs than the parent strain, an improvement that ranged from 25-217% for each 
individual product (Fig. 30). 
 
Figure 30. The synthesis of MCFAs from evolved strains compared to those from parental strain YJZ02. 
Taken together, engineering efforts including protein engineering, pathway optimization and 
cellular fitness improvement were applied to dramatically improve the production of MCFAs. 
These versatile strategies could also be used to benefit the production of other toxic 
chemicals. 
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4 Summary, conclusion and perspectives 
 
 
 
In past decades, the advances in biotechnology have offered great opportunities to expand 
the diversity of chemicals produced by microbes and enabled efficient microbial cell 
factories. The specific demands on titer, rate and yield are essential for the development 
from a proof-of-concept strain to a cell factory that could be utilized for industrial 
production. This is a time-consuming and most challenging road that requires numerous 
modifications and optimizations in metabolic pathways, enzymes of interest and the 
fermentation process. Combining diverse engineering strategies, free fatty acids have been 
produced at high titers of 33.4 g/L57, providing a potential precursor pool for further 
formation of valuable chemicals. Compared with free fatty acids, fatty acid derivatives 
possess wider applications such as biofuels and biomaterials197,198. As described above, our 
work focused on the improved production of several fatty acid derivatives in S. cerevisiae, 
such as fatty alcohols, MCFAs and MCFOHs, through multidimensional engineering 
approaches.  
The low viability of cells and the complicated extraction process are major obstacles for 
industrial fatty alcohol production. In order to solve these problems, we attempted to 
identify a transporter able to functionally export fatty alcohols from the yeast S. cerevisiae. 
Thus, in Paper I, mammalian transporter FATP1 was found in yeast to promote the export of 
fatty alcohols in yeast. The expression of FATP1 resulted an increased cell fitness and 4.5-
fold higher extracellular fatty alcohols compared with the control strain. FATP1 was reported 
as a membrane-bound acyl-CoA synthetase specific to very long chain fatty acids, and 
involved in uptake of long chain fatty acids199,200. Further efforts towards functional domain 
identification were made through domain exchange between FATP1 and FATP4. In this part 
of the work, we highlight the possibility that transporter engineering could be a promising 
strategy to enable the successful commercialization of biofuel production. Transporter 
engineering was further applied in our next work. 
In Paper II, the yeast S. cerevisiae was engineered to enable a relatively high production of 1-
alkenes through dynamically regulating their synthesis and transporter engineering. PfUndB 
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from P. fluorescens Pf-5 showed high enzyme activity towards 1-alkene formation and was 
found to locate to the membrane. Dynamic control of PfUndB was performed to relieve the 
toxicity of expressing the membrane protein, together with cofactor engineering by 
expressing the NADH-dependent Pdx/Pdr system, yielding a 4-fold increase in 1-alkene 
production compared with the control strain. FATP1 was found to facilitate the export of 1-
alkenes as well in this study; its expression contributed to a 40% increase in extracellular 1-
alkene production. Different from the performance in the fatty alcohol producing strain, 
FATP1 only had a marginal effect on the cell growth. This suggested that the toxicity of 1-
alkenes is not the bottleneck at the current stage in contract to fatty alcohols. The low 
catalytic activity of the key enzymes involved in 1-alkene formation is rather the major 
problem that demands prompt solution.  
The optimization of a type I FAS in a previous study enabled the selective synthesis of MCFAs 
in yeast59,60. In Paper III, both the endogenous FAS and an orthogonal bacterial type I FAS 
were engineered for MCFA production in S. cerevisiae. Owing to the development of 
engineering strategies, the titers of MCFAs currently produced by engineered yeast cells 
have already approached the inhibitory concentration of MCFAs105,201,202. Thus, directed 
evolution of the transporter Tpo1 and adaptive laboratory evolution were implemented to 
increase cellular tolerance against toxic MCFAs with the consequence of 2.3- and 2.7- fold 
improvement in MCFA production, respectively. The mutants that conferred resistance to 
MCFAs during ALE were further characterized after performing genome sequencing of three 
evolved strains. However, due to the poor understanding of the Tpo1 transporter, it was 
difficult to deduce the possible mechanism of the altered amino acid residues. We further 
enlarged the precursor supply, which combined with these modifications, resulted in a final 
production of >1 g/L MCFAs and the highest yield (0.053 g/g glucose) reported in yeast so 
far. This high MCFA production platform strain could be considered as the provider of a 
precursor pool for the production of a range of MCFA-derived chemicals. 
Based on our work described above, we further engineered MmCAR from Mycobacterium 
marinum for selective synthesis of MCFOHs in yeast through multiple protein engineering 
strategies in Paper IV. Based on high-throughput screening coupled with cell growth, a 
random mutagenesis approach was conducted based on the full-length MmCAR, and 50% 
more MCFOHs were produced by the best variant. Both a random mutagenesis approach 
and rational design based on its structure information were performed to the A domain of 
MmCAR, which successfully changed the substrate specificity to MCFAs, and the best 
mutation I303W resulted in a 1.6-fold increase in MCFOH production. The R domain 
modification through the semi-rational design toward residues 983-985 turned out to be the 
most efficient strategy that increased the final titer of MCFOHs 2.1-fold compared with the 
control strain. In combination with these efficient mutations, a final 3-fold increase in 
MCFOHs was achieved with the additional deletion of transporter Tpo1. In this part of work, 
the engineered MmCAR offered abundant production of MCFOHs and aldehydes as the 
versatile intermediates that enable broad applications for further formation of alka(e)nes 
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and FAEEs. However, the impaired growth caused by the toxicity of MCFOHs still is a major 
obstacle for future industrial production like MCFAs. Thus, the improvement of cellular 
tolerance against MCFOHs through fermentation process optimization and transporter 
engineering would be feasible strategies to obtain a further increase in MCFOH production.  
We could clearly demonstrate that transporter engineering plays a very important role for 
the improved production of oleochemicals, especially of toxic chemicals that might cause 
impaired cell growth. In our work, the expression of a heterologous transporter has been 
proven to significantly benefit the export of fatty alcohols and alkenes, which would be of 
great commercial interest in reducing the cost of the final product extraction. However, the 
expression of heterologous transporters for improved production and secretion has not 
been widely studied due to many reasons. The poor understanding of transporters is one of 
the main reasons, as the substrates of many transporters have not been fully identified and 
the transporters for many products of commercial interests are still unknown. In addition, 
the difficulties of functionally expressing heterologous transporters could be caused by the 
discrepancy of membrane structures between different species and the negative effects on 
cell viability. We therefore brought up an alternative approach in our study, an improved 
activity of native transporter Tpo1 was achieved through protein engineering to benefit the 
cellular tolerance against toxic chemicals, resulting an improved production of MCFAs. This 
strategy could perfectly circumvent the necessity of functionally expressing a heterologous 
transporter, but it requires that the native one should ideally already possess some basic 
activity towards the substrates of interest. The protein engineering approach was also 
highlighted in our work where the key enzyme MmCAR involved in fatty alcohol formation 
was engineered to enable a changed specificity towards MCFAs. However, the application of 
this strategy is still limited by our knowledge of structural information and the screening 
method. The development in the accuracy of structural prediction based on computational 
structure modeling would play a very important role for further experimental investigation. 
Ultra-high-throughput screening method that could be achieved by the advances in 
instrumentation of reading and analysis would also confer critical contributions in future 
applications. Moreover, practical protein engineering methods towards non-typical proteins 
that have no structural information and screening method available would be a future 
direction to be developed along with the technical advances.  
As mentioned, it is still challenging to meet the commercial requirements for the microbial 
production of fatty acid derivatives. The cellular toxicity caused by the accumulation of these 
chemicals is one of the major problems for large-scale industrial production. Transporter 
engineering, adaptive evolution and fermentation process optimization need to be further 
developed to improve the cellular tolerance and product secretion. Moreover, in many 
cases, the relatively low activity of the key enzymes is still the major obstacle, such as for 
alka(e)ne production in yeast. Besides achieving better performance by protein engineering 
towards the target enzymes, the development of high-throughput methods would also allow 
for rapid selection among large amounts of enzyme candidates. In addition, as the 
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oleochemicals possess relatively low value, increasing the utilization of carbon sources by 
changing to single carbon feedstocks, such as CO2 and methanol, is also another feasible 
strategy to obtain high TRY metrics that needs to be extensively studied. The progress of 
metabolic engineering benefits from great developments in the field of biotechnology, for 
example, the CRISPR technology has significantly shortened the time of genetic manipulation 
in microbes. However, based on the “Design-Build-Test-Learn” (DBTL) cycle203, learning is 
probably the most challenging part that requires more novel analysis tools to get new insight 
into optimization of microbes and proteins of interest. The development of next-generation 
sequencing in omics analysis and machine-learning techniques could provide a deeper 
understanding about the regulation and interaction of metabolites and proteins inside the 
cell, which would benefit the exploitation of new engineering targets.         
In conclusion, this thesis clearly indicates that the engineered yeast cells provide great 
opportunities to produce diverse chemicals. Besides the traditional metabolic pathway 
engineering, multidimensional engineering at the protein level and the cellular level leading 
to an improved tolerance against toxic chemicals will also play crucial roles in enhancing the 
TRY metrics in yeast.  
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